{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "fb14bb3b-1c64-4cab-a733-49430a51d662",
   "metadata": {},
   "source": [
    "### Extract Text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "16ec379d-c337-4469-bd24-e0e4f028e504",
   "metadata": {},
   "outputs": [],
   "source": [
    "import fitz  # PyMuPDF\n",
    "\n",
    "def extract_text_from_pdf(file_path):\n",
    "    doc = fitz.open(file_path)\n",
    "    pages = []\n",
    "    for page_number in range(len(doc)):\n",
    "        page = doc.load_page(page_number)\n",
    "        text = page.get_text().strip()\n",
    "        pages.append({\n",
    "            \"page_number\": page_number + 1,\n",
    "            \"text\": text\n",
    "        })\n",
    "    doc.close()\n",
    "    return pages\n",
    "\n",
    "# Extract and print text\n",
    "pdf_path = \"./metformin1.pdf\"\n",
    "pages = extract_text_from_pdf(pdf_path)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0f378cc9-6dda-4bb8-b38d-fa42ffb8f5e9",
   "metadata": {},
   "source": [
    "### Extract Entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0f4ddd01-bfeb-4a65-b1a7-1b5f1850eb8b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "nlp = spacy.load(\"en_core_web_sm\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "05175d8e-8f62-47ea-8d92-153ec4cd3cbb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Function to extract entities from text\n",
    "def extract_entities(text):\n",
    "    doc = nlp(text)\n",
    "    entities = []\n",
    "    for ent in doc.ents:\n",
    "        entities.append({\n",
    "            \"text\": ent.text,\n",
    "            \"label\": ent.label_\n",
    "        })\n",
    "    return entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "aa3a2de0-0cb3-4876-bd57-30c82840714d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'page_number': 1, 'entities': [{'text': '2', 'label': 'CARDINAL'}, {'text': 'Metformin', 'label': 'PERSON'}, {'text': 'C4H11N5 •', 'label': 'ORG'}, {'text': '165.63', 'label': 'CARDINAL'}, {'text': '12.4', 'label': 'CARDINAL'}, {'text': '1%', 'label': 'PERCENT'}, {'text': '6.68', 'label': 'CARDINAL'}, {'text': '500', 'label': 'CARDINAL'}, {'text': '850', 'label': 'CARDINAL'}, {'text': '1000', 'label': 'CARDINAL'}, {'text': '500', 'label': 'CARDINAL'}, {'text': '850', 'label': 'CARDINAL'}, {'text': '1000', 'label': 'CARDINAL'}, {'text': '500', 'label': 'CARDINAL'}, {'text': '750', 'label': 'CARDINAL'}, {'text': '500', 'label': 'CARDINAL'}, {'text': '4079189', 'label': 'CARDINAL'}, {'text': 'FDA', 'label': 'ORG'}, {'text': 'https://www.fda.gov/drugsatfda', 'label': 'ORG'}]}\n"
     ]
    }
   ],
   "source": [
    "all_entities = []\n",
    "\n",
    "for page in pages:\n",
    "    entities = extract_entities(page[\"text\"])\n",
    "    all_entities.append({\n",
    "        \"page_number\": page[\"page_number\"],\n",
    "        \"entities\": entities\n",
    "    })\n",
    "\n",
    "print(all_entities[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e4213738",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "\n",
    "with open(\"entities.json\", \"w\", encoding=\"utf-8\") as f:\n",
    "    json.dump(all_entities, f, ensure_ascii=False, indent=2)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4b2c0ff7",
   "metadata": {},
   "source": [
    "### Unique labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a49b4853",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['CARDINAL', 'DATE', 'GPE', 'LAW', 'LOC', 'NORP', 'ORDINAL', 'ORG', 'PERCENT', 'PERSON', 'PRODUCT', 'QUANTITY', 'TIME', 'WORK_OF_ART']\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "# Load the JSON back in\n",
    "with open(\"entities.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)\n",
    "\n",
    "# Collect all unique labels\n",
    "unique_labels = {entity[\"label\"] for page in data for entity in page[\"entities\"]}\n",
    "\n",
    "# Turn into a sorted list if you want them ordered\n",
    "unique_labels = sorted(unique_labels)\n",
    "\n",
    "print(unique_labels)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1aa9e481-dc25-43cf-9257-790a4c8c6d32",
   "metadata": {},
   "source": [
    "### Building and storing your FAISS index"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "79623823",
   "metadata": {},
   "source": [
    "### Ollama Function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "15b9ead4",
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "\n",
    "def ask_ollama(prompt):\n",
    "    url = \"http://home-pc.tail4924f5.ts.net:11434/api/generate\"\n",
    "    headers = {\n",
    "        \"Content-Type\": \"application/json\"\n",
    "    }\n",
    "    payload = {\n",
    "        \"model\": \"llama3\",\n",
    "        \"prompt\": prompt,\n",
    "        \"stream\": False\n",
    "    }\n",
    "\n",
    "    response = requests.post(url, headers=headers, json=payload)\n",
    "    response.raise_for_status()\n",
    "    \n",
    "    return response.json()[\"response\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "c317b4cd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Nice to meet you! I'm LLaMA, a large language model trained by a team of researcher at Meta AI. My primary function is to understand and respond to human input in the form of text or voice. I'm a conversational AI designed to simulate natural language understanding and generation.\\n\\nI can help with a wide range of topics, from general knowledge and history to science, technology, culture, and more. I can also engage in creative activities like storytelling, poetry, and even humor.\\n\\nWhat would you like to talk about or ask me?\""
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ask_ollama(\"Hello who are you\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "774aa4b9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "569"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "# Load the uploaded entities.json file\n",
    "with open(\"entities.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)\n",
    "\n",
    "# Create a set of unique (label, text) pairs\n",
    "unique_entities = {(ent[\"label\"], ent[\"text\"]) for page in data for ent in page[\"entities\"]}\n",
    "\n",
    "# Count unique entities\n",
    "unique_count = len(unique_entities)\n",
    "unique_count"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0fb71df1-8ce8-43a9-a261-e59178c7d8b7",
   "metadata": {},
   "source": [
    "### Dumping nodes in Neo4J"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "6e27cfb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# --- 2. Neo4j Aura connection --\n",
    "from neo4j import GraphDatabase\n",
    "\n",
    "NEO4J_URI = \"neo4j+s://033a4c34.databases.neo4j.io\"\n",
    "NEO4J_USER = \"neo4j\"\n",
    "NEO4J_PASSWORD = \"yQ02-iiANgP8fMDa_Ndj6mq4DioXPbbqGdP2_JBqrLg\"\n",
    "driver = GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USER, NEO4J_PASSWORD))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "38188ae4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Neo4j connection successful!\n"
     ]
    }
   ],
   "source": [
    "def test_connection():\n",
    "    try:\n",
    "        with driver.session() as session:\n",
    "            result = session.run(\"RETURN 'Neo4j connection successful!' AS message\")\n",
    "            print(result.single()[\"message\"])\n",
    "    except Exception as e:\n",
    "        print(\"❌ Failed to connect to Neo4j:\", e)\n",
    "\n",
    "test_connection()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "a0f6aeea",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/35/143126m50gv7zq_ldk50bbhr0000gn/T/ipykernel_36551/2032268651.py:25: DeprecationWarning: write_transaction has been renamed to execute_write\n",
      "  session.write_transaction(create_nodes, unique_entities)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Inserted 568 unique nodes.\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "# --- 1. Load entities.json ---\n",
    "with open(\"entities.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)\n",
    "\n",
    "# --- 3. Collect unique (label, text) pairs ---\n",
    "unique_entities = set()\n",
    "for page in data:\n",
    "    for ent in page[\"entities\"]:\n",
    "        label = ent[\"label\"].strip()\n",
    "        text = ent[\"text\"].strip()\n",
    "        unique_entities.add((label, text))\n",
    "\n",
    "# --- 4. Create nodes in Neo4j ---\n",
    "def create_nodes(tx, entities):\n",
    "    for label, text in entities:\n",
    "        # MERGE avoids duplicates if you re-run the script\n",
    "        query = f\"\"\"\n",
    "        MERGE (n:`{label}` {{text: $text}})\n",
    "        \"\"\"\n",
    "        tx.run(query, text=text)\n",
    "\n",
    "with driver.session() as session:\n",
    "    session.write_transaction(create_nodes, unique_entities)\n",
    "\n",
    "print(f\"Inserted {len(unique_entities)} unique nodes.\")\n",
    "\n",
    "driver.close()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cc7010ef",
   "metadata": {},
   "source": [
    "## Semantic Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "9a797fd2",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "def chunk_pages(pages, chunk_size=1000, chunk_overlap=200):\n",
    "    splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=chunk_size,\n",
    "        chunk_overlap=chunk_overlap\n",
    "    )\n",
    "    all_chunks = []\n",
    "    for page in pages:\n",
    "        chunks = splitter.split_text(page[\"text\"])\n",
    "        all_chunks.extend(chunks)\n",
    "    return all_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "19db0aa1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Chunk 1 ---\n",
      "926 GLUCOPHAGE®  \n",
      "(metformin hydrochloride) Tablets  \n",
      "GLUCOPHAGE® XR  \n",
      "(metformin hydrochloride) Extended-Release Tablets  \n",
      "DESCRIPTION \n",
      "GLUCOPHAGE® (metformin hydrochloride) Tablets and GLUCOPHAGE® XR (metformin \n",
      "hydrochloride) Extended-Release Tablets are oral antihyperglycemic drugs used in the \n",
      "management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic \n",
      "diamide hydrochloride) is not chemically or pharmacologically related to any other classes of \n",
      "oral antihyperglycemic agents. The structural formula is as shown: structural formula\n",
      "Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula \n",
      "of C4H11N5 • HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble \n",
      "in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is \n",
      "12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.\n",
      "\n",
      "--- Chunk 2 ---\n",
      "916 in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is \n",
      "12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. \n",
      "GLUCOPHAGE tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Each \n",
      "tablet contains the inactive ingredients povidone and magnesium stearate. In addition, the coating \n",
      "for the 500 mg and 850 mg tablets contains hypromellose and the coating for the 1000 mg tablet \n",
      "contains hypromellose and polyethylene glycol. \n",
      "GLUCOPHAGE XR contains 500 mg or 750 mg of metformin hydrochloride as the active \n",
      "ingredient. \n",
      "GLUCOPHAGE XR 500 mg tablets contain the inactive ingredients sodium carboxymethyl \n",
      "cellulose, hypromellose, microcrystalline cellulose, and magnesium stearate. \n",
      "1\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 3 ---\n",
      "992 GLUCOPHAGE XR 750 mg tablets contain the inactive ingredients sodium carboxymethyl \n",
      "cellulose, hypromellose, and magnesium stearate. \n",
      "System Components and Performance–GLUCOPHAGE XR comprises a dual hydrophilic \n",
      "polymer matrix system. Metformin hydrochloride is combined with a drug release controlling \n",
      "polymer to form an \"inner\" phase, which is then incorporated as discrete particles into an \n",
      "\"external\" phase of a second polymer. After administration, fluid from the gastrointestinal (GI) \n",
      "tract enters the tablet, causing the polymers to hydrate and swell. Drug is released slowly from \n",
      "the dosage form by a process of diffusion through the gel matrix that is essentially independent \n",
      "of pH. The hydrated polymer system is not rigid and is expected to be broken up by normal \n",
      "peristalsis in the GI tract. The biologically inert components of the tablet may occasionally \n",
      "remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass. \n",
      "CLINICAL PHARMACOLOGY\n",
      "\n",
      "--- Chunk 4 ---\n",
      "970 remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass. \n",
      "CLINICAL PHARMACOLOGY \n",
      "Mechanism of Action \n",
      "Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type \n",
      "2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms \n",
      "of action are different from other classes of oral antihyperglycemic agents. Metformin decreases \n",
      "hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin \n",
      "sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, \n",
      "metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal \n",
      "subjects (except in special circumstances, see PRECAUTIONS) and does not cause \n",
      "hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting \n",
      "insulin levels and day-long plasma insulin response may actually decrease. \n",
      "Pharmacokinetics\n",
      "\n",
      "--- Chunk 5 ---\n",
      "972 hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting \n",
      "insulin levels and day-long plasma insulin response may actually decrease. \n",
      "Pharmacokinetics \n",
      "Absorption and Bioavailability \n",
      "The absolute bioavailability of a GLUCOPHAGE 500 mg tablet given under fasting conditions \n",
      "is approximately 50% to 60%. Studies using single oral doses of GLUCOPHAGE 500 to \n",
      "1500 mg, and 850 to 2550 mg, indicate that there is a lack of dose proportionality with \n",
      "increasing doses, which is due to decreased absorption rather than an alteration in elimination. \n",
      "Food decreases the extent of and slightly delays the absorption of metformin, as shown by \n",
      "approximately a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the \n",
      "plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak \n",
      "plasma concentration (Tmax) following administration of a single 850 mg tablet of metformin \n",
      "2\n",
      "Reference ID: 4079189\n",
      "\n",
      "--- Chunk 6 ---\n",
      "247 plasma concentration (Tmax) following administration of a single 850 mg tablet of metformin \n",
      "2\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 7 ---\n",
      "991 with food, compared to the same tablet strength administered fasting. The clinical relevance of \n",
      "these decreases is unknown. \n",
      "Following a single oral dose of GLUCOPHAGE XR, Cmax is achieved with a median value of \n",
      "7 hours and a range of 4 to 8 hours. Peak plasma levels are approximately 20% lower compared \n",
      "to the same dose of GLUCOPHAGE, however, the extent of absorption (as measured by AUC) \n",
      "is similar to GLUCOPHAGE. \n",
      "At steady state, the AUC and Cmax are less than dose proportional for GLUCOPHAGE XR \n",
      "within the range of 500 to 2000 mg administered once daily. Peak plasma levels are \n",
      "approximately 0.6, 1.1, 1.4, and 1.8 µg/mL for 500, 1000, 1500, and 2000 mg once-daily doses, \n",
      "respectively. The extent of metformin absorption (as measured by AUC) from \n",
      "GLUCOPHAGE XR at a 2000 mg once-daily dose is similar to the same total daily dose \n",
      "administered as GLUCOPHAGE tablets 1000 mg twice daily. After repeated administration of \n",
      "GLUCOPHAGE XR, metformin did not accumulate in plasma.\n",
      "\n",
      "--- Chunk 8 ---\n",
      "934 administered as GLUCOPHAGE tablets 1000 mg twice daily. After repeated administration of \n",
      "GLUCOPHAGE XR, metformin did not accumulate in plasma. \n",
      "Within-subject variability in Cmax and AUC of metformin from GLUCOPHAGE XR is \n",
      "comparable to that with GLUCOPHAGE. \n",
      "Although the extent of metformin absorption (as measured by AUC) from the \n",
      "GLUCOPHAGE XR tablet increased by approximately 50% when given with food, there was no \n",
      "effect of food on Cmax and Tmax of metformin. Both high and low fat meals had the same effect \n",
      "on the pharmacokinetics of GLUCOPHAGE XR. \n",
      "Distribution \n",
      "The apparent volume of distribution (V/F) of metformin following single oral doses of \n",
      "GLUCOPHAGE 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma \n",
      "proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin \n",
      "partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing\n",
      "\n",
      "--- Chunk 9 ---\n",
      "821 proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin \n",
      "partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing \n",
      "schedules of GLUCOPHAGE, steady state plasma concentrations of metformin are reached \n",
      "within 24 to 48 hours and are generally <1 µg/mL. During controlled clinical trials of \n",
      "GLUCOPHAGE, maximum metformin plasma levels did not exceed 5 µg/mL, even at maximum \n",
      "doses. \n",
      "Metabolism and Elimination \n",
      "Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted \n",
      "unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been \n",
      "3\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 10 ---\n",
      "994 identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately \n",
      "3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major \n",
      "route of metformin elimination. Following oral administration, approximately 90% of the \n",
      "absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma \n",
      "elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is \n",
      "approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of \n",
      "distribution. \n",
      "Specific Populations \n",
      "Patients with Type 2 Diabetes \n",
      "In the presence of normal renal function, there are no differences between single- or multiple-\n",
      "dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects \n",
      "(see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses. \n",
      "The pharmacokinetics of GLUCOPHAGE XR in patients with type 2 diabetes are comparable to\n",
      "\n",
      "--- Chunk 11 ---\n",
      "934 (see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses. \n",
      "The pharmacokinetics of GLUCOPHAGE XR in patients with type 2 diabetes are comparable to \n",
      "those in healthy normal adults. \n",
      "Renal Impairment \n",
      "In patients with decreased renal function, the plasma and blood half-life of metformin is \n",
      "prolonged \n",
      "and \n",
      "the\n",
      "CONTRAINDICATIONS, \n",
      "ADMINISTRATION). \n",
      " \n",
      "renal \n",
      "clearance \n",
      "is \n",
      "decreased\n",
      "WARNINGS, \n",
      "PRECAUTIONS,\n",
      " \n",
      "(see \n",
      "Table \n",
      " \n",
      "and \n",
      "D\n",
      "1;\n",
      "OSAGE\n",
      " \n",
      "also \n",
      "see \n",
      "AND \n",
      "Hepatic Impairment \n",
      "No pharmacokinetic studies of metformin have been conducted in patients with hepatic \n",
      "insufficiency (see PRECAUTIONS). \n",
      "Geriatrics \n",
      "Limited data from controlled pharmacokinetic studies of GLUCOPHAGE in healthy elderly \n",
      "subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, \n",
      "and Cmax is increased, compared to healthy young subjects. From these data, it appears that the\n",
      "\n",
      "--- Chunk 12 ---\n",
      "538 subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, \n",
      "and Cmax is increased, compared to healthy young subjects. From these data, it appears that the \n",
      "change in metformin pharmacokinetics with aging is primarily accounted for by a change in \n",
      "renal function (see Table 1; also see WARNINGS, PRECAUTIONS, and DOSAGE AND \n",
      "ADMINISTRATION). \n",
      "4\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 13 ---\n",
      "990 Table 1: Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or \n",
      "Multiple Oral Doses of GLUCOPHAGE \n",
      "Subject Groups: GLUCOPHAGE dosea \n",
      "(number of subjects) \n",
      "Cmax \n",
      "b \n",
      "(µg/mL) \n",
      "Tmax \n",
      "c \n",
      "(hrs) \n",
      "Renal Clearance \n",
      "(mL/min) \n",
      "Healthy, nondiabetic adults: \n",
      "500 mg single dose (24) \n",
      "850 mg single dose (74)d \n",
      "850 mg three times daily for 19 dosese (9) \n",
      "1.03 (±0.33) \n",
      "1.60 (±0.38) \n",
      "2.01 (±0.42) \n",
      "2.75 (±0.81) \n",
      "2.64 (±0.82) \n",
      "1.79 (±0.94) \n",
      "600 (±132) \n",
      "552 (±139) \n",
      "642 (±173) \n",
      "Adults with type 2 diabetes: \n",
      "850 mg single dose (23) \n",
      "850 mg three times daily for 19 dosese (9) \n",
      "1.48 (±0.5) \n",
      "1.90 (±0.62) \n",
      "3.32 (±1.08) \n",
      "2.01 (±1.22) \n",
      "491 (±138) \n",
      "550 (±160) \n",
      "Elderlyf, healthy nondiabetic adults: \n",
      "850 mg single dose (12) \n",
      "2.45 (±0.70) \n",
      "2.71 (±1.05) \n",
      "412 (±98) \n",
      "Renal-impaired adults: \n",
      "850 mg single dose \n",
      "Mild (CLcr \n",
      "g 61-90 mL/min) (5) \n",
      "Moderate (CLcr 31-60 mL/min) (4) \n",
      "Severe (CLcr 10-30 mL/min) (6) \n",
      "1.86 (±0.52) \n",
      "4.12 (±1.83) \n",
      "3.93 (±0.92) \n",
      "3.20 (±0.45) \n",
      "3.75 (±0.50) \n",
      "4.01 (±1.10)\n",
      "\n",
      "--- Chunk 14 ---\n",
      "965 Mild (CLcr \n",
      "g 61-90 mL/min) (5) \n",
      "Moderate (CLcr 31-60 mL/min) (4) \n",
      "Severe (CLcr 10-30 mL/min) (6) \n",
      "1.86 (±0.52) \n",
      "4.12 (±1.83) \n",
      "3.93 (±0.92) \n",
      "3.20 (±0.45) \n",
      "3.75 (±0.50) \n",
      "4.01 (±1.10) \n",
      "384 (±122) \n",
      "108 (±57) \n",
      "130 (±90) \n",
      "a All doses given fasting except the first 18 doses of the multiple dose studies \n",
      "b Peak plasma concentration \n",
      "c Time to peak plasma concentration \n",
      "d Combined results (average means) of five studies: mean age 32 years (range 23-59 years) \n",
      "e Kinetic study done following dose 19, given fasting \n",
      "f Elderly subjects, mean age 71 years (range 65-81 years) \n",
      "g \n",
      "2\n",
      "CLcr = creatinine clearance normalized to body surface area of 1.73 m\n",
      "Pediatrics \n",
      "After administration of a single oral GLUCOPHAGE 500 mg tablet with food, geometric mean \n",
      "metformin Cmax and AUC differed less than 5% between pediatric type 2 diabetic patients \n",
      "(12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all \n",
      "with normal renal function. \n",
      "Gender\n",
      "\n",
      "--- Chunk 15 ---\n",
      "473 (12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all \n",
      "with normal renal function. \n",
      "Gender \n",
      "Metformin pharmacokinetic parameters did not differ significantly between normal subjects and \n",
      "patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16). \n",
      "5\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 16 ---\n",
      "925 Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic \n",
      "effect of GLUCOPHAGE was comparable in males and females. \n",
      "Race \n",
      "No studies of metformin pharmacokinetic parameters according to race have been performed. In \n",
      "controlled clinical studies of GLUCOPHAGE in patients with type 2 diabetes, the \n",
      "antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics \n",
      "(n=24). \n",
      "Clinical Studies \n",
      "GLUCOPHAGE \n",
      "In a double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with \n",
      "type 2 diabetes whose hyperglycemia was not adequately controlled with dietary management \n",
      "alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL), treatment with \n",
      "GLUCOPHAGE (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in \n",
      "fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL,\n",
      "\n",
      "--- Chunk 17 ---\n",
      "985 GLUCOPHAGE (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in \n",
      "fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL, \n",
      "83 mg/dL, and 1.8%, respectively, compared to the placebo group (see Table 2). \n",
      "Table 2: GLUCOPHAGE vs Placebo Summary of Mean Changes from Baseline* in \n",
      "Fasting Plasma Glucose, HbA1c, and Body Weight, at Final Visit (29-week study) \n",
      "GLUCOPHAGE \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "p-Value \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "241.5 \n",
      "–53.0 \n",
      "237.7 \n",
      "6.3 \n",
      "NS** \n",
      "0.001 \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "8.4 \n",
      "–1.4 \n",
      "8.2 \n",
      "0.4 \n",
      "NS** \n",
      "0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "201.0 \n",
      "–1.4 \n",
      "206.0 \n",
      "–2.4 \n",
      "NS** \n",
      "NS** \n",
      "* All patients on diet therapy at Baseline \n",
      "** Not statistically significant \n",
      "A 29-week, double-blind, placebo-controlled study of GLUCOPHAGE and glyburide, alone and \n",
      "in combination, was conducted in obese patients with type 2 diabetes who had failed to achieve\n",
      "\n",
      "--- Chunk 18 ---\n",
      "790 A 29-week, double-blind, placebo-controlled study of GLUCOPHAGE and glyburide, alone and \n",
      "in combination, was conducted in obese patients with type 2 diabetes who had failed to achieve \n",
      "adequate glycemic control while on maximum doses of glyburide (baseline FPG of \n",
      "approximately 250 mg/dL) (see Table 3). Patients randomized to the combination arm started \n",
      "therapy with GLUCOPHAGE 500 mg and glyburide 20 mg. At the end of each week of the first \n",
      "4 weeks of the trial, these patients had their dosages of GLUCOPHAGE increased by 500 mg if \n",
      "they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments \n",
      "6\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 19 ---\n",
      "969 were made monthly, although no patient was allowed to exceed GLUCOPHAGE 2500 mg. \n",
      "Patients in the GLUCOPHAGE only arm (metformin plus placebo) followed the same titration \n",
      "schedule. At the end of the trial, approximately 70% of the patients in the combination group \n",
      "were taking GLUCOPHAGE 2000 mg/glyburide 20 mg or GLUCOPHAGE 2500 mg/glyburide \n",
      "20 mg. Patients randomized to continue on glyburide experienced worsening of glycemic \n",
      "control, with mean increases in FPG, PPG, and HbA1c of 14 mg/dL, 3 mg/dL, and 0.2%, \n",
      "respectively. In contrast, those randomized to GLUCOPHAGE (up to 2500 mg/day) experienced \n",
      "a slight improvement, with mean reductions in FPG, PPG, and HbA1c of 1 mg/dL, 6 mg/dL, and \n",
      "0.4%, respectively. The combination of GLUCOPHAGE and glyburide was effective in reducing \n",
      "FPG, PPG, and HbA1c levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to \n",
      "results of glyburide treatment alone, the net differences with combination treatment were\n",
      "\n",
      "--- Chunk 20 ---\n",
      "956 FPG, PPG, and HbA1c levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to \n",
      "results of glyburide treatment alone, the net differences with combination treatment were \n",
      "–77 mg/dL, –68 mg/dL, and –1.9%, respectively (see Table 3). \n",
      "Table 3: Combined GLUCOPHAGE/Glyburide (Comb) vs Glyburide (Glyb) or \n",
      "GLUCOPHAGE (GLU) Monotherapy: Summary of Mean Changes from Baseline* in \n",
      "Fasting Plasma Glucose, HbA1c, and Body Weight, at Final Visit (29-week study) \n",
      "Comb \n",
      "(n=213) \n",
      "Glyb \n",
      "(n=209) \n",
      "GLU \n",
      "(n=210) \n",
      "p-values \n",
      "Glyb vs \n",
      "Comb \n",
      "GLU vs \n",
      "Comb \n",
      "GLU vs \n",
      "Glyb \n",
      "Fasting Plasma Glucose (mg/dL) \n",
      "Baseline \n",
      "250.5 \n",
      "247.5 \n",
      "253.9 \n",
      "NS** \n",
      "NS** \n",
      "NS** \n",
      "Change at FINAL VISIT \n",
      "–63.5 \n",
      "13.7 \n",
      "–0.9 \n",
      "0.001 \n",
      "0.001 \n",
      "0.025 \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "8.8 \n",
      "8.5 \n",
      "8.9 \n",
      "NS** \n",
      "NS** \n",
      "0.007 \n",
      "Change at FINAL VISIT \n",
      "–1.7 \n",
      "0.2 \n",
      "–0.4 \n",
      "0.001 \n",
      "0.001 \n",
      "0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "202.2 \n",
      "203.0 \n",
      "204.0 \n",
      "NS** \n",
      "NS** \n",
      "NS** \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "–0.7 \n",
      "–8.4 \n",
      "0.011 \n",
      "0.001 \n",
      "0.001\n",
      "\n",
      "--- Chunk 21 ---\n",
      "925 0.007 \n",
      "Change at FINAL VISIT \n",
      "–1.7 \n",
      "0.2 \n",
      "–0.4 \n",
      "0.001 \n",
      "0.001 \n",
      "0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "202.2 \n",
      "203.0 \n",
      "204.0 \n",
      "NS** \n",
      "NS** \n",
      "NS** \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "–0.7 \n",
      "–8.4 \n",
      "0.011 \n",
      "0.001 \n",
      "0.001 \n",
      "* All patients on glyburide, 20 mg/day, at Baseline \n",
      "** Not statistically significant \n",
      "The magnitude of the decline in fasting blood glucose concentration following the institution of \n",
      "GLUCOPHAGE Tablets therapy was proportional to the level of fasting hyperglycemia. Patients \n",
      "with type 2 diabetes with higher fasting glucose concentrations experienced greater declines in \n",
      "plasma glucose and glycosylated hemoglobin. \n",
      "In clinical studies, GLUCOPHAGE, alone or in combination with a sulfonylurea, lowered mean \n",
      "fasting serum triglycerides, total cholesterol, and LDL cholesterol levels, and had no adverse \n",
      "effects on other lipid levels (see Table 4). \n",
      "7\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "\n",
      "--- Chunk 22 ---\n",
      "200 effects on other lipid levels (see Table 4). \n",
      "7\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 23 ---\n",
      "939 Table 4: Summary of Mean Percent Change From Baseline of Major Serum Lipid \n",
      "Variables at Final Visit (29-week studies) \n",
      "GLUCOPHAGE vs \n",
      "Placebo \n",
      "Combined GLUCOPHAGE/Glyburide \n",
      "vs Monotherapy \n",
      "GLUCOPHAGE \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "GLUCOPHAGE \n",
      "(n=210) \n",
      "GLUCOPHAGE/ \n",
      "Glyburide \n",
      "(n=213) \n",
      "Glyburide \n",
      "(n=209) \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "211.0 \n",
      "–5% \n",
      "212.3 \n",
      "1% \n",
      "213.1 \n",
      "–2% \n",
      "215.6 \n",
      "–4% \n",
      "219.6 \n",
      "1% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "236.1 \n",
      "–16% \n",
      "203.5 \n",
      "1% \n",
      "242.5 \n",
      "–3% \n",
      "215.0 \n",
      "–8% \n",
      "266.1 \n",
      "4% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "135.4 \n",
      "–8% \n",
      "138.5 \n",
      "1% \n",
      "134.3 \n",
      "–4% \n",
      "136.0 \n",
      "–6% \n",
      "137.5 \n",
      "3% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "39.0 \n",
      "2% \n",
      "40.5 \n",
      "–1% \n",
      "37.2 \n",
      "5% \n",
      "39.0 \n",
      "3% \n",
      "37.0 \n",
      "1% \n",
      "In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tended to remain \n",
      "stable or even decrease somewhat (see Tables 2 and 3).\n",
      "\n",
      "--- Chunk 24 ---\n",
      "956 39.0 \n",
      "2% \n",
      "40.5 \n",
      "–1% \n",
      "37.2 \n",
      "5% \n",
      "39.0 \n",
      "3% \n",
      "37.0 \n",
      "1% \n",
      "In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tended to remain \n",
      "stable or even decrease somewhat (see Tables 2 and 3). \n",
      "A 24-week, double-blind, placebo-controlled study of GLUCOPHAGE plus insulin versus \n",
      "insulin plus placebo was conducted in patients with type 2 diabetes who failed to achieve \n",
      "adequate glycemic control on insulin alone (see Table 5). Patients randomized to receive \n",
      "GLUCOPHAGE plus insulin achieved a reduction in HbA1c of 2.10%, compared to a 1.56% \n",
      "reduction in HbA1c achieved by insulin plus placebo. The improvement in glycemic control was \n",
      "achieved at the final study visit with 16% less insulin, 93.0 U/day vs 110.6 U/day, \n",
      "GLUCOPHAGE plus insulin versus insulin plus placebo, respectively, p=0.04. \n",
      "8\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 25 ---\n",
      "976 Table 5: Combined GLUCOPHAGE/Insulin vs Placebo/Insulin Summary of Mean \n",
      "Changes from Baseline in HbA1c and Daily Insulin Dose \n",
      "GLUCOPHAGE/ \n",
      "Insulin \n",
      "(n=26) \n",
      "Placebo/ \n",
      "Insulin \n",
      "(n=28) \n",
      "Treatment \n",
      "Difference \n",
      "Mean ± SE \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "8.95 \n",
      "–2.10 \n",
      "9.32 \n",
      "–1.56 \n",
      "–0.54 ± 0.43a \n",
      "Insulin Dose (U/day) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "93.12 \n",
      "–0.15 \n",
      "94.64 \n",
      "15.93 \n",
      "–16.08 ± 7.77b \n",
      "a Statistically significant using analysis of covariance with baseline as covariate (p=0.04)  \n",
      "Not significant using analysis of variance (values shown in table)  \n",
      "b Statistically significant for insulin (p=0.04) \n",
      "A second double-blind, placebo-controlled study (n=51), with 16 weeks of randomized \n",
      "treatment, demonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks \n",
      "with an average HbA1c of 7.46 ± 0.97%, the addition of GLUCOPHAGE maintained similar \n",
      "glycemic control (HbA1c 7.15 ± 0.61 vs 6.97 ± 0.62 for GLUCOPHAGE plus insulin and\n",
      "\n",
      "--- Chunk 26 ---\n",
      "973 with an average HbA1c of 7.46 ± 0.97%, the addition of GLUCOPHAGE maintained similar \n",
      "glycemic control (HbA1c 7.15 ± 0.61 vs 6.97 ± 0.62 for GLUCOPHAGE plus insulin and \n",
      "placebo plus insulin, respectively) with 19% less insulin versus baseline (reduction of 23.68 ± \n",
      "30.22 vs an increase of 0.43 ± 25.20 units for GLUCOPHAGE plus insulin and placebo plus \n",
      "insulin, p<0.01). In addition, this study demonstrated that the combination of GLUCOPHAGE \n",
      "plus insulin resulted in reduction in body weight of 3.11 ± 4.30 lbs, compared to an increase of \n",
      "1.30 ± 6.08 lbs for placebo plus insulin, p=0.01. \n",
      "GLUCOPHAGE XR \n",
      "A 24-week, double-blind, placebo-controlled study of GLUCOPHAGE XR, taken once daily \n",
      "with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve \n",
      "glycemic control with diet and exercise (HbA1c 7.0%-10.0%, FPG 126-270 mg/dL). Patients \n",
      "entering the study had a mean baseline HbA1c of 8.0% and a mean baseline FPG of 176 mg/dL.\n",
      "\n",
      "--- Chunk 27 ---\n",
      "923 glycemic control with diet and exercise (HbA1c 7.0%-10.0%, FPG 126-270 mg/dL). Patients \n",
      "entering the study had a mean baseline HbA1c of 8.0% and a mean baseline FPG of 176 mg/dL. \n",
      "After 12 weeks treatment, mean HbA1c had increased from baseline by 0.1% and mean FPG \n",
      "decreased from baseline by 2 mg/dL in the placebo group, compared with a decrease in mean \n",
      "HbA1c of 0.6% and a decrease in mean FPG of 23 mg/dL in patients treated with \n",
      "GLUCOPHAGE XR 1000 mg once daily. Subsequently, the treatment dose was increased to \n",
      "1500 mg once daily if HbA1c was ≥7.0% but <8.0% (patients with HbA1c ≥8.0% were \n",
      "discontinued from the study). At the final visit (24-week), mean HbA1c had increased 0.2% from \n",
      "baseline in placebo patients and decreased 0.6% with GLUCOPHAGE XR. \n",
      "9\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 28 ---\n",
      "994 A 16-week, double-blind, placebo-controlled, dose-response study of GLUCOPHAGE XR, \n",
      "taken once daily with the evening meal or twice daily with meals, was conducted in patients with \n",
      "type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA1c 7.0%­\n",
      "11.0%, FPG 126-280 mg/dL). Changes in glycemic control and body weight are shown in Table \n",
      "6. \n",
      "Table 6: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, \n",
      "and Body Weight at Final Visit (16-week study) \n",
      "GLUCOPHAGE XR \n",
      "Placebo \n",
      "500 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Once \n",
      "Daily \n",
      "1500 mg \n",
      "Once \n",
      "Daily \n",
      "2000 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Twice \n",
      "Daily \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=115) \n",
      "8.2 \n",
      "–0.4 \n",
      "<0.001 \n",
      "(n=115) \n",
      "8.4 \n",
      "–0.6 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.3 \n",
      "–0.9 \n",
      "<0.001 \n",
      "(n=125) \n",
      "8.4 \n",
      "–0.8 \n",
      "<0.001 \n",
      "(n=112) \n",
      "8.4 \n",
      "–1.1 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.4 \n",
      "0.1 \n",
      "– \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=126) \n",
      "182.7 \n",
      "–15.2 \n",
      "<0.001 \n",
      "(n=118) \n",
      "183.7 \n",
      "–19.3 \n",
      "<0.001 \n",
      "(n=120) \n",
      "178.9\n",
      "\n",
      "--- Chunk 29 ---\n",
      "929 –0.8 \n",
      "<0.001 \n",
      "(n=112) \n",
      "8.4 \n",
      "–1.1 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.4 \n",
      "0.1 \n",
      "– \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=126) \n",
      "182.7 \n",
      "–15.2 \n",
      "<0.001 \n",
      "(n=118) \n",
      "183.7 \n",
      "–19.3 \n",
      "<0.001 \n",
      "(n=120) \n",
      "178.9 \n",
      "–28.5 \n",
      "<0.001 \n",
      "(n=132) \n",
      "181.0 \n",
      "–29.9 \n",
      "<0.001 \n",
      "(n=122) \n",
      "181.6 \n",
      "–33.6 \n",
      "<0.001 \n",
      "(n=113) \n",
      "179.6 \n",
      "7.6 \n",
      "– \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=125) \n",
      "192.9 \n",
      "–1.3 \n",
      "NS** \n",
      "(n=119) \n",
      "191.8 \n",
      "–1.3 \n",
      "NS** \n",
      "(n=117) \n",
      "188.3 \n",
      "–0.7 \n",
      "NS** \n",
      "(n=131) \n",
      "195.4 \n",
      "–1.5 \n",
      "NS** \n",
      "(n=119) \n",
      "192.5 \n",
      "–2.2 \n",
      "NS** \n",
      "(n=113) \n",
      "194.3 \n",
      "–1.8 \n",
      "– \n",
      "* All patients on diet therapy at Baseline \n",
      "a All comparisons versus Placebo \n",
      "** Not statistically significant \n",
      "Compared with placebo, improvement in glycemic control was seen at all dose levels of \n",
      "GLUCOPHAGE XR Extended-Release Tablets and treatment was not associated with any \n",
      "significant change in weight (see DOSAGE AND ADMINISTRATION for dosing \n",
      "recommendations for GLUCOPHAGE and GLUCOPHAGE XR).\n",
      "\n",
      "--- Chunk 30 ---\n",
      "876 significant change in weight (see DOSAGE AND ADMINISTRATION for dosing \n",
      "recommendations for GLUCOPHAGE and GLUCOPHAGE XR). \n",
      "A 24-week, double-blind, randomized study of GLUCOPHAGE XR, taken once daily with the \n",
      "evening meal, and GLUCOPHAGE Tablets, taken twice daily (with breakfast and evening \n",
      "meal), was conducted in patients with type 2 diabetes who had been treated with \n",
      "GLUCOPHAGE 500 mg twice daily for at least 8 weeks prior to study entry. The \n",
      "GLUCOPHAGE dose had not necessarily been titrated to achieve a specific level of glycemic \n",
      "control prior to study entry. Patients qualified for the study if HbA1c was ≤8.5% and FPG was \n",
      "≤200 mg/dL. Changes in glycemic control and body weight are shown in Table 7. \n",
      "10 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 31 ---\n",
      "980 Table 7: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, \n",
      "and Body Weight at Week 12 and at Final Visit (24-week study) \n",
      "GLUCOPHAGE \n",
      "500 mg \n",
      "Twice Daily \n",
      "GLUCOPHAGE XR \n",
      "1000 mg \n",
      "Once Daily \n",
      "1500 mg \n",
      "Once Daily \n",
      "Hemoglobin A1c (%) \n",
      "(n=67) \n",
      "(n=72) \n",
      "(n=66) \n",
      "Baseline \n",
      "7.06 \n",
      "6.99 \n",
      "7.02 \n",
      "Change at 12 Weeks \n",
      "0.14 \n",
      "0.23 \n",
      "0.04 \n",
      "(95% CI) \n",
      "(–0.03, 0.31) \n",
      "(0.10, 0.36) \n",
      "(–0.08, 0.15) \n",
      "Change at FINAL VISIT \n",
      "0.14a \n",
      "0.27 \n",
      "0.13 \n",
      "(95% CI) \n",
      "(–0.04, 0.31) \n",
      "(0.11, 0.43) \n",
      "(–0.02, 0.28) \n",
      "FPG (mg/dL) \n",
      "(n=69) \n",
      "(n=72) \n",
      "(n=70) \n",
      "Baseline \n",
      "127.2 \n",
      "131.0 \n",
      "131.4 \n",
      "Change at 12 Weeks \n",
      "12.9 \n",
      "9.5 \n",
      "3.7 \n",
      "(95% CI) \n",
      "(6.5, 19.4) \n",
      "(4.4, 14.6) \n",
      "(–0.4, 7.8) \n",
      "Change at FINAL VISIT \n",
      "14.0 \n",
      "11.5 \n",
      "7.6 \n",
      "(95% CI) \n",
      "(7.0, 21.0) \n",
      "(4.4, 18.6) \n",
      "(1.0, 14.2) \n",
      "Body Weight (lbs) \n",
      "(n=71) \n",
      "(n=74) \n",
      "(n=71) \n",
      "Baseline \n",
      "210.3 \n",
      "202.8 \n",
      "192.7 \n",
      "Change at 12 Weeks \n",
      "0.4 \n",
      "0.9 \n",
      "0.7 \n",
      "(95% CI) \n",
      "(–0.4, 1.5) \n",
      "(0.0, 2.0) \n",
      "(–0.4, 1.8) \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "1.1 \n",
      "0.9 \n",
      "(95% CI) \n",
      "(–0.4, 2.2) \n",
      "(–0.2, 2.4) \n",
      "(–0.4, 2.0)\n",
      "\n",
      "--- Chunk 32 ---\n",
      "770 210.3 \n",
      "202.8 \n",
      "192.7 \n",
      "Change at 12 Weeks \n",
      "0.4 \n",
      "0.9 \n",
      "0.7 \n",
      "(95% CI) \n",
      "(–0.4, 1.5) \n",
      "(0.0, 2.0) \n",
      "(–0.4, 1.8) \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "1.1 \n",
      "0.9 \n",
      "(95% CI) \n",
      "(–0.4, 2.2) \n",
      "(–0.2, 2.4) \n",
      "(–0.4, 2.0) \n",
      "* All patients on GLUCOPHAGE 500 mg twice daily at Baseline \n",
      "a n=68 \n",
      "After 12 weeks of treatment, there was an increase in mean HbA1c in all groups; in the \n",
      "GLUCOPHAGE XR 1000 mg group, the increase from baseline of 0.23% was statistically \n",
      "significant (see DOSAGE AND ADMINISTRATION). \n",
      "Changes in lipid parameters in the previously described placebo-controlled dose-response study \n",
      "of GLUCOPHAGE XR are shown in Table 8. \n",
      "11 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 33 ---\n",
      "997 Table 8: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at \n",
      "Final Visit (16-week study) \n",
      "GLUCOPHAGE XR \n",
      "Placebo \n",
      "500 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Once \n",
      "Daily \n",
      "1500 mg \n",
      "Once \n",
      "Daily \n",
      "2000 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Twice \n",
      "Daily \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "210.3 \n",
      "1.0% \n",
      "(n=113) \n",
      "218.1 \n",
      "1.7% \n",
      "(n=110) \n",
      "214.6 \n",
      "0.7% \n",
      "(n=126) \n",
      "204.4 \n",
      "–1.6% \n",
      "(n=117) \n",
      "208.2 \n",
      "–2.6% \n",
      "(n=110) \n",
      "208.6 \n",
      "2.6% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "220.2 \n",
      "14.5% \n",
      "(n=113) \n",
      "211.9 \n",
      "9.4% \n",
      "(n=110) \n",
      "198.0 \n",
      "15.1% \n",
      "(n=126) \n",
      "194.2 \n",
      "14.9% \n",
      "(n=117) \n",
      "179.0 \n",
      "9.4% \n",
      "(n=110) \n",
      "211.7 \n",
      "10.9% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=119) \n",
      "131.0 \n",
      "–1.4% \n",
      "(n=113) \n",
      "134.9 \n",
      "–1.6% \n",
      "(n=109) \n",
      "135.8 \n",
      "–3.5% \n",
      "(n=126) \n",
      "125.8 \n",
      "–3.3% \n",
      "(n=117) \n",
      "131.4 \n",
      "–5.5% \n",
      "(n=107) \n",
      "131.9 \n",
      "3.2% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "40.8 \n",
      "6.2% \n",
      "(n=108) \n",
      "41.6 \n",
      "8.6% \n",
      "(n=108) \n",
      "40.6 \n",
      "5.5% \n",
      "(n=125) \n",
      "40.2\n",
      "\n",
      "--- Chunk 34 ---\n",
      "561 –3.3% \n",
      "(n=117) \n",
      "131.4 \n",
      "–5.5% \n",
      "(n=107) \n",
      "131.9 \n",
      "3.2% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "40.8 \n",
      "6.2% \n",
      "(n=108) \n",
      "41.6 \n",
      "8.6% \n",
      "(n=108) \n",
      "40.6 \n",
      "5.5% \n",
      "(n=125) \n",
      "40.2 \n",
      "6.1% \n",
      "(n=117) \n",
      "42.4 \n",
      "7.1% \n",
      "(n=108) \n",
      "39.4 \n",
      "5.8% \n",
      "* All patients on diet therapy at Baseline \n",
      "Changes in lipid parameters in the previously described study of GLUCOPHAGE and \n",
      "GLUCOPHAGE XR are shown in Table 9. \n",
      "12 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 35 ---\n",
      "995 Table 9: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at \n",
      "Final Visit (24-week study) \n",
      "GLUCOPHAGE \n",
      "GLUCOPHAGE XR \n",
      "500 mg \n",
      "Twice Daily \n",
      "1000 mg \n",
      "Once Daily \n",
      "1500 mg \n",
      "Once Daily \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "199.0 \n",
      "0.1% \n",
      "(n=70) \n",
      "201.9 \n",
      "1.3% \n",
      "(n=66) \n",
      "201.6 \n",
      "0.1% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "178.0 \n",
      "6.3% \n",
      "(n=70) \n",
      "169.2 \n",
      "25.3% \n",
      "(n=66) \n",
      "206.8 \n",
      "33.4% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "122.1 \n",
      "−1.3% \n",
      "(n=70) \n",
      "126.2 \n",
      "−3.3% \n",
      "(n=66) \n",
      "115.7 \n",
      "−3.7% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "41.9 \n",
      "4.8% \n",
      "(n=70) \n",
      "41.7 \n",
      "1.0% \n",
      "(n=65) \n",
      "44.6 \n",
      "–2.1% \n",
      "* All patients on GLUCOPHAGE 500 mg twice daily at Baseline \n",
      "Pediatric Clinical Studies \n",
      "In a double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type \n",
      "2 diabetes (mean FPG 182.2 mg/dL), treatment with GLUCOPHAGE (up to 2000 mg/day) for\n",
      "\n",
      "--- Chunk 36 ---\n",
      "952 In a double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type \n",
      "2 diabetes (mean FPG 182.2 mg/dL), treatment with GLUCOPHAGE (up to 2000 mg/day) for \n",
      "up to 16 weeks (mean duration of treatment 11 weeks) resulted in a significant mean net \n",
      "reduction in FPG of 64.3 mg/dL, compared with placebo (see Table 10). \n",
      "Table 10: GLUCOPHAGE vs Placebo (Pediatricsa) Summary of Mean Changes from \n",
      "Baseline* in Plasma Glucose and Body Weight at Final Visit \n",
      "GLUCOPHAGE \n",
      "Placebo \n",
      "p-Value \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "(n=37) \n",
      "162.4 \n",
      "–42.9 \n",
      "(n=36) \n",
      "192.3 \n",
      "21.4 \n",
      "<0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "(n=39) \n",
      "205.3 \n",
      "–3.3 \n",
      "(n=38) \n",
      "189.0 \n",
      "–2.0 \n",
      "NS** \n",
      "a Pediatric patients mean age 13.8 years (range 10-16 years) \n",
      "* All patients on diet therapy at Baseline \n",
      "** Not statistically significant \n",
      "INDICATIONS AND USAGE \n",
      "GLUCOPHAGE (metformin hydrochloride) Tablets is indicated as an adjunct to diet and\n",
      "\n",
      "--- Chunk 37 ---\n",
      "434 * All patients on diet therapy at Baseline \n",
      "** Not statistically significant \n",
      "INDICATIONS AND USAGE \n",
      "GLUCOPHAGE (metformin hydrochloride) Tablets is indicated as an adjunct to diet and \n",
      "exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. \n",
      "13 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 38 ---\n",
      "986 GLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets is indicated as an \n",
      "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. \n",
      "CONTRAINDICATIONS \n",
      "GLUCOPHAGE and GLUCOPHAGE XR are contraindicated in patients with: \n",
      "1.  Severe renal impairment (eGFR below 30 mL/min/1.73 m2) (see WARNINGS and \n",
      "PRECAUTIONS). \n",
      "2.  Known hypersensitivity to metformin hydrochloride. \n",
      "3.  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without \n",
      "coma. Diabetic ketoacidosis should be treated with insulin. \n",
      "WARNINGS \n",
      "WARNING: LACTIC ACIDOSIS \n",
      "Postmarketing cases of metformin-associated lactic acidosis have resulted in death, \n",
      "hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin­\n",
      "associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such \n",
      "as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin­\n",
      "associated \n",
      "lactic \n",
      "acidosis \n",
      "was\n",
      "\n",
      "--- Chunk 39 ---\n",
      "930 as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin­\n",
      "associated \n",
      "lactic \n",
      "acidosis \n",
      "was \n",
      "characterized \n",
      "by \n",
      "elevated \n",
      "blood \n",
      "lactate \n",
      "levels \n",
      "(>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an \n",
      "increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL (see \n",
      "PRECAUTIONS). \n",
      "Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use \n",
      "of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or \n",
      "greater, having a radiological study with contrast, surgery and other procedures, hypoxic states \n",
      "(e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. \n",
      "Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk \n",
      "groups are provided (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, \n",
      "and PRECAUTIONS).\n",
      "\n",
      "--- Chunk 40 ---\n",
      "571 Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk \n",
      "groups are provided (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, \n",
      "and PRECAUTIONS). \n",
      "If metformin-associated lactic acidosis is suspected, immediately discontinue GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and institute general supportive measures in a hospital setting. Prompt \n",
      "hemodialysis is recommended (see PRECAUTIONS). \n",
      "14 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 41 ---\n",
      "916 PRECAUTIONS \n",
      "General \n",
      "•  Lactic acidosis—There have been postmarketing cases of metformin-associated lactic \n",
      "acidosis, including fatal cases. These cases had a subtle onset and were accompanied by \n",
      "nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or \n",
      "increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred \n",
      "with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated \n",
      "blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria \n",
      "or ketonemia), and an increased lactate:pyruvate ratio; metformin plasma levels were \n",
      "generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood \n",
      "levels which may increase the risk of lactic acidosis, especially in patients at risk. \n",
      "If metformin-associated lactic acidosis is suspected, general supportive measures should be\n",
      "\n",
      "--- Chunk 42 ---\n",
      "987 levels which may increase the risk of lactic acidosis, especially in patients at risk. \n",
      "If metformin-associated lactic acidosis is suspected, general supportive measures should be \n",
      "instituted promptly in a hospital setting, along with immediate discontinuation of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. In GLUCOPHAGE or GLUCOPHAGE XR \n",
      "treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is \n",
      "recommended to correct the acidosis and remove accumulated metformin (metformin \n",
      "hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic \n",
      "conditions). Hemodialysis has often resulted in reversal of symptoms and recovery. \n",
      "Educate patients and their families about the symptoms of lactic acidosis and, if these \n",
      "symptoms occur, instruct them to discontinue GLUCOPHAGE or GLUCOPHAGE XR and \n",
      "report these symptoms to their healthcare provider. \n",
      "For each of the known and possible risk factors for metformin-associated lactic acidosis,\n",
      "\n",
      "--- Chunk 43 ---\n",
      "874 report these symptoms to their healthcare provider. \n",
      "For each of the known and possible risk factors for metformin-associated lactic acidosis, \n",
      "recommendations to reduce the risk of and manage metformin-associated lactic acidosis are \n",
      "provided below: \n",
      "•  Renal impairment—The postmarketing metformin-associated lactic acidosis cases primarily \n",
      "occurred in patients with significant renal impairment. \n",
      "The risk of metformin accumulation and metformin-associated lactic acidosis increases with \n",
      "the severity of renal impairment because metformin is substantially excreted by the kidney.  \n",
      "Clinical recommendations based upon the patient’s renal function include (see DOSAGE \n",
      "AND ADMINISTRATION, CLINICAL PHARMACOLOGY): \n",
      "15 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 44 ---\n",
      "992 o  Before initiating GLUCOPHAGE or GLUCOPHAGE XR, obtain an estimated \n",
      "glomerular filtration rate (eGFR) \n",
      "o  GLUCOPHAGE or GLUCOPHAGE XR is contraindicated in patients with an eGFR less \n",
      "than 30 mL/min/1.73 m2 (see CONTRAINDICATIONS). \n",
      "o  Initiation of GLUCOPHAGE or GLUCOPHAGE XR is not recommended in patients \n",
      "with eGFR between 30-45 mL/min/1.73 m2 . \n",
      "o  Obtain an eGFR at least annually in all patients taking GLUCOPHAGE or \n",
      "GLUCOPHAGE XR. In patients at risk for the development of renal impairment (e.g., \n",
      "the elderly), renal function should be assessed more frequently. \n",
      "o  In patients taking GLUCOPHAGE or GLUCOPHAGE XR whose eGFR falls below \n",
      "45 mL/min/1.73 m2, assess the benefit and risk of continuing therapy. \n",
      "•  Drug interactions—The concomitant use of GLUCOPHAGE or GLUCOPHAGE XR with \n",
      "specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair \n",
      "renal function, result in significant hemodynamic change, interfere with acid-base balance, or\n",
      "\n",
      "--- Chunk 45 ---\n",
      "916 specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair \n",
      "renal function, result in significant hemodynamic change, interfere with acid-base balance, or \n",
      "increase metformin accumulation. Consider more frequent monitoring of patients. \n",
      "•  Age 65 or greater—The risk of metformin-associated lactic acidosis increases with the \n",
      "patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or \n",
      "cardiac impairment than younger patients. Assess renal function more frequently in elderly \n",
      "patients. \n",
      "•  Radiologic studies with contrast—Administration of intravascular iodinated contrast agents \n",
      "in metformin-treated patients has led to an acute decrease in renal function and the \n",
      "occurrence of lactic acidosis. Stop GLUCOPHAGE or GLUCOPHAGE XR at the time of, or \n",
      "prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and\n",
      "\n",
      "--- Chunk 46 ---\n",
      "931 occurrence of lactic acidosis. Stop GLUCOPHAGE or GLUCOPHAGE XR at the time of, or \n",
      "prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and \n",
      "60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart \n",
      "failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate \n",
      "eGFR 48 hours after the imaging procedure, and restart GLUCOPHAGE or GLUCOPHAGE \n",
      "XR if renal function is stable. \n",
      "•  Surgery and other procedures—Withholding of food and fluids during surgical or other \n",
      "procedures may increase the risk for volume depletion, hypotension, and renal impairment. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR should be temporarily discontinued while patients \n",
      "have restricted food and fluid intake. \n",
      "16 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 47 ---\n",
      "987 •  Hypoxic states—Several of the postmarketing cases of metformin-associated lactic acidosis \n",
      "occurred in the setting of acute congestive heart failure (particularly when accompanied by \n",
      "hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial \n",
      "infarction, sepsis, and other conditions associated with hypoxemia have been associated with \n",
      "lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "•  Excessive alcohol intake—Alcohol is known to potentiate the effect of metformin on lactate \n",
      "metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or \n",
      "chronic, while receiving GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "•  Hepatic impairment—Patients with hepatic impairment have developed cases of metformin­\n",
      "associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher \n",
      "lactate blood levels. Therefore, avoid use of GLUCOPHAGE and GLUCOPHAGE XR in\n",
      "\n",
      "--- Chunk 48 ---\n",
      "973 associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher \n",
      "lactate blood levels. Therefore, avoid use of GLUCOPHAGE and GLUCOPHAGE XR in \n",
      "patients with clinical or laboratory evidence of hepatic disease. \n",
      "Vitamin B12 levels—In controlled clinical trials of GLUCOPHAGE of 29 weeks duration, a \n",
      "decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical \n",
      "manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to \n",
      "interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely \n",
      "associated with anemia and appears to be rapidly reversible with discontinuation of \n",
      "GLUCOPHAGE or vitamin B12 supplementation. Measurement of hematologic parameters on an \n",
      "annual basis is advised in patients on GLUCOPHAGE or GLUCOPHAGE XR and any apparent \n",
      "abnormalities should be appropriately investigated and managed (see PRECAUTIONS: \n",
      "Laboratory Tests).\n",
      "\n",
      "--- Chunk 49 ---\n",
      "968 annual basis is advised in patients on GLUCOPHAGE or GLUCOPHAGE XR and any apparent \n",
      "abnormalities should be appropriately investigated and managed (see PRECAUTIONS: \n",
      "Laboratory Tests). \n",
      "Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to \n",
      "be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum \n",
      "vitamin B12 measurements at 2- to 3-year intervals may be useful. \n",
      "Hypoglycemia—Hypoglycemia does not occur in patients receiving GLUCOPHAGE or \n",
      "GLUCOPHAGE XR alone under usual circumstances of use, but could occur when caloric \n",
      "intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or \n",
      "during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or \n",
      "ethanol. \n",
      "17 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 50 ---\n",
      "979 Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or \n",
      "alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be \n",
      "difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. \n",
      "Macrovascular outcomes—There have been no clinical studies establishing conclusive evidence \n",
      "of macrovascular risk reduction with GLUCOPHAGE or GLUCOPHAGE XR or any other \n",
      "antidiabetic drug. \n",
      "Information for Patients \n",
      "Patients should be informed of the potential risks and benefits of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and of alternative modes of therapy. They should also be informed about \n",
      "the importance of adherence to dietary instructions, of a regular exercise program, and of regular \n",
      "testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters. \n",
      "The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as\n",
      "\n",
      "--- Chunk 51 ---\n",
      "955 testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters. \n",
      "The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as \n",
      "noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. \n",
      "Patients should be advised to discontinue GLUCOPHAGE or GLUCOPHAGE XR immediately \n",
      "and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, \n",
      "unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any \n",
      "dose level of GLUCOPHAGE or GLUCOPHAGE XR, gastrointestinal symptoms, which are \n",
      "common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence \n",
      "of gastrointestinal symptoms could be due to lactic acidosis or other serious disease. \n",
      "Patients should be counseled against excessive alcohol intake, either acute or chronic, while \n",
      "receiving GLUCOPHAGE or GLUCOPHAGE XR.\n",
      "\n",
      "--- Chunk 52 ---\n",
      "962 Patients should be counseled against excessive alcohol intake, either acute or chronic, while \n",
      "receiving GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR alone does not usually cause hypoglycemia, although it \n",
      "may occur when GLUCOPHAGE or GLUCOPHAGE XR is used in conjunction with oral \n",
      "sulfonylureas and insulin. When initiating combination therapy, the risks of hypoglycemia, its \n",
      "symptoms and treatment, and conditions that predispose to its development should be explained \n",
      "to patients and responsible family members. (See Patient Information printed below.) \n",
      "Patients should be informed that GLUCOPHAGE XR must be swallowed whole and not crushed \n",
      "or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft \n",
      "mass that may resemble the original tablet. \n",
      "18 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 53 ---\n",
      "968 Laboratory Tests \n",
      "Response to all diabetic therapies should be monitored by periodic measurements of fasting \n",
      "blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward \n",
      "the normal range. During initial dose titration, fasting glucose can be used to determine the \n",
      "therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be \n",
      "monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating \n",
      "long-term control (see also DOSAGE AND ADMINISTRATION). \n",
      "Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red \n",
      "blood cell indices) and renal function (serum creatinine) should be performed, at least on an \n",
      "annual basis. While megaloblastic anemia has rarely been seen with GLUCOPHAGE therapy, if \n",
      "this is suspected, vitamin B12 deficiency should be excluded. \n",
      "Instruct patients to inform their doctor that they are taking GLUCOPHAGE or GLUCOPHAGE\n",
      "\n",
      "--- Chunk 54 ---\n",
      "981 this is suspected, vitamin B12 deficiency should be excluded. \n",
      "Instruct patients to inform their doctor that they are taking GLUCOPHAGE or GLUCOPHAGE \n",
      "XR prior to any surgical or radiological procedure, as temporary discontinuation of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR may be required until renal function has been \n",
      "confirmed to be normal (see PRECAUTIONS). \n",
      "Drug Interactions (Clinical Evaluation of Drug Interactions Conducted \n",
      "with GLUCOPHAGE) \n",
      "Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of \n",
      "metformin and glyburide did not result in any changes in either metformin pharmacokinetics or \n",
      "pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly \n",
      "variable. The single-dose nature of this study and the lack of correlation between glyburide blood \n",
      "levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain \n",
      "(see \n",
      "DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: \n",
      "Concomitant \n",
      "GLUCOPHAGE \n",
      "or\n",
      "\n",
      "--- Chunk 55 ---\n",
      "954 levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain \n",
      "(see \n",
      "DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: \n",
      "Concomitant \n",
      "GLUCOPHAGE \n",
      "or \n",
      "GLUCOPHAGE XR and Oral Sulfonylurea Therapy in Adult Patients). \n",
      "Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects \n",
      "demonstrated that pharmacokinetic parameters of both compounds were affected by \n",
      "coadministration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood \n",
      "AUC by 15%, without any significant change in metformin renal clearance. When administered \n",
      "with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than \n",
      "when administered alone, and the terminal half-life was decreased by 32%, without any \n",
      "significant change in furosemide renal clearance. No information is available about the \n",
      "interaction of metformin and furosemide when coadministered chronically. \n",
      "19 \n",
      "Reference ID: 4079189\n",
      "\n",
      "--- Chunk 56 ---\n",
      "319 significant change in furosemide renal clearance. No information is available about the \n",
      "interaction of metformin and furosemide when coadministered chronically. \n",
      "19 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 57 ---\n",
      "961 Nifedipine—A single-dose, metformin-nifedipine drug interaction study in normal healthy \n",
      "volunteers demonstrated that coadministration of nifedipine increased plasma metformin Cmax \n",
      "and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and \n",
      "half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin \n",
      "had minimal effects on nifedipine. \n",
      "Drugs that reduce metformin clearance—Concomitant use of drugs that interfere with common \n",
      "renal tubular transport systems involved in the renal elimination of metformin (e.g., organic \n",
      "cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as \n",
      "ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to \n",
      "metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of \n",
      "concomitant use. Such interaction between metformin and oral cimetidine has been observed in\n",
      "\n",
      "--- Chunk 58 ---\n",
      "933 metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of \n",
      "concomitant use. Such interaction between metformin and oral cimetidine has been observed in \n",
      "normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug \n",
      "interaction studies, with a 60% increase in peak metformin plasma and whole blood \n",
      "concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no \n",
      "change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine \n",
      "pharmacokinetics. \n",
      "In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and \n",
      "ibuprofen were not affected when coadministered in single-dose interaction studies. \n",
      "Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with \n",
      "highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid,\n",
      "\n",
      "--- Chunk 59 ---\n",
      "991 Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with \n",
      "highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, \n",
      "as compared to the sulfonylureas, which are extensively bound to serum proteins. \n",
      "Other—Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. \n",
      "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid \n",
      "products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium \n",
      "channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving \n",
      "GLUCOPHAGE or GLUCOPHAGE XR, the patient should be closely observed for loss of \n",
      "blood glucose control. When such drugs are withdrawn from a patient receiving GLUCOPHAGE \n",
      "or GLUCOPHAGE XR, the patient should be observed closely for hypoglycemia. \n",
      "Carbonic \n",
      "anhydrase \n",
      "inhibitors—Topiramate \n",
      "or \n",
      "other \n",
      "carbonic \n",
      "anhydrase \n",
      "inhibitors\n",
      "\n",
      "--- Chunk 60 ---\n",
      "648 or GLUCOPHAGE XR, the patient should be observed closely for hypoglycemia. \n",
      "Carbonic \n",
      "anhydrase \n",
      "inhibitors—Topiramate \n",
      "or \n",
      "other \n",
      "carbonic \n",
      "anhydrase \n",
      "inhibitors \n",
      "(e.g., zonisamide, acetazolamide or dichlorphenamide) frequently cause a decrease in serum \n",
      "bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of \n",
      "these drugs with GLUCOPHAGE or GLUCOPHAGE XR may increase the risk for lactic \n",
      "acidosis. Consider more frequent monitoring of these patients. \n",
      "20 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 61 ---\n",
      "969 Alcohol—Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn \n",
      "patients against excessive alcohol intake while receiving GLUCOPHAGE OR GLUCOPHAGE \n",
      "XR. \n",
      "Carcinogenesis, Mutagenesis, Impairment of Fertility \n",
      "Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) \n",
      "and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and \n",
      "1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum \n",
      "recommended human daily dose of 2000 mg based on body surface area comparisons. No \n",
      "evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, \n",
      "there was no tumorigenic potential observed with metformin in male rats. There was, however, \n",
      "an increased incidence of benign stromal uterine polyps in female rats treated with \n",
      "900 mg/kg/day. \n",
      "There was no evidence of a mutagenic potential of metformin in the following in vitro tests:\n",
      "\n",
      "--- Chunk 62 ---\n",
      "956 an increased incidence of benign stromal uterine polyps in female rats treated with \n",
      "900 mg/kg/day. \n",
      "There was no evidence of a mutagenic potential of metformin in the following in vitro tests: \n",
      "Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal \n",
      "aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also \n",
      "negative. \n",
      "Fertility of male or female rats was unaffected by metformin when administered at doses as high \n",
      "as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily \n",
      "dose based on body surface area comparisons. \n",
      "Pregnancy \n",
      "Teratogenic Effects: Pregnancy Category B \n",
      "Recent information strongly suggests that abnormal blood glucose levels during pregnancy are \n",
      "associated with a higher incidence of congenital abnormalities. Most experts recommend that \n",
      "insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.\n",
      "\n",
      "--- Chunk 63 ---\n",
      "870 associated with a higher incidence of congenital abnormalities. Most experts recommend that \n",
      "insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. \n",
      "Because animal reproduction studies are not always predictive of human response, \n",
      "GLUCOPHAGE and GLUCOPHAGE XR should not be used during pregnancy unless clearly \n",
      "needed. \n",
      "There are no adequate and well-controlled studies in pregnant women with GLUCOPHAGE or \n",
      "GLUCOPHAGE XR. Metformin was not teratogenic in rats and rabbits at doses up to \n",
      "600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended \n",
      "human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, \n",
      "21 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 64 ---\n",
      "970 respectively. Determination of fetal concentrations demonstrated a partial placental barrier to \n",
      "metformin. \n",
      "Nursing Mothers \n",
      "Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable \n",
      "to those in plasma. Similar studies have not been conducted in nursing mothers. Because the \n",
      "potential for hypoglycemia in nursing infants may exist, a decision should be made whether to \n",
      "discontinue nursing or to discontinue the drug, taking into account the importance of the drug to \n",
      "the mother. If GLUCOPHAGE or GLUCOPHAGE XR is discontinued, and if diet alone is \n",
      "inadequate for controlling blood glucose, insulin therapy should be considered. \n",
      "Pediatric Use \n",
      "The safety and effectiveness of GLUCOPHAGE for the treatment of type 2 diabetes have been \n",
      "established in pediatric patients ages 10 to 16 years (studies have not been conducted in pediatric \n",
      "patients below the age of 10 years). Use of GLUCOPHAGE in this age group is supported by\n",
      "\n",
      "--- Chunk 65 ---\n",
      "961 established in pediatric patients ages 10 to 16 years (studies have not been conducted in pediatric \n",
      "patients below the age of 10 years). Use of GLUCOPHAGE in this age group is supported by \n",
      "evidence from adequate and well-controlled studies of GLUCOPHAGE in adults with additional \n",
      "data from a controlled clinical study in pediatric patients ages 10 to 16 years with type \n",
      "2 diabetes, which demonstrated a similar response in glycemic control to that seen in adults. (See \n",
      "CLINICAL PHARMACOLOGY: Pediatric Clinical Studies.) In this study, adverse effects \n",
      "were similar to those described in adults. (See ADVERSE REACTIONS: Pediatric Patients.) \n",
      "A maximum \n",
      "daily dose \n",
      "of \n",
      "2000 \n",
      "mg \n",
      "is \n",
      "recommended. \n",
      "(See DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: Recommended Dosing Schedule: Pediatrics.) \n",
      "Safety and effectiveness of GLUCOPHAGE XR in pediatric patients have not been established. \n",
      "Geriatric Use \n",
      "Controlled clinical studies of GLUCOPHAGE and GLUCOPHAGE XR did not include\n",
      "\n",
      "--- Chunk 66 ---\n",
      "999 Safety and effectiveness of GLUCOPHAGE XR in pediatric patients have not been established. \n",
      "Geriatric Use \n",
      "Controlled clinical studies of GLUCOPHAGE and GLUCOPHAGE XR did not include \n",
      "sufficient numbers of elderly patients to determine whether they respond differently from \n",
      "younger patients, although other reported clinical experience has not identified differences in \n",
      "responses between the elderly and younger patients. \n",
      "In general, dose selection for an elderly patient should be cautious, usually starting at the low end \n",
      "of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac \n",
      "function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. \n",
      "Assess renal function more frequently in elderly patients (see WARNINGS, PRECAUTIONS, \n",
      "and DOSAGE AND ADMINISTRATION). \n",
      "22 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 67 ---\n",
      "928 ADVERSE REACTIONS \n",
      "In a US double-blind clinical study of GLUCOPHAGE in patients with type 2 diabetes, a total of \n",
      "141 patients received GLUCOPHAGE therapy (up to 2550 mg per day) and 145 patients \n",
      "received placebo. Adverse reactions reported in greater than 5% of the GLUCOPHAGE patients, \n",
      "and that were more common in GLUCOPHAGE- than placebo-treated patients, are listed in \n",
      "Table 11. \n",
      "Table 11: Most Common Adverse Reactions (>5.0 Percent) in a Placebo-Controlled \n",
      "Clinical Study of GLUCOPHAGE Monotherapy* \n",
      "Adverse Reaction \n",
      "GLUCOPHAGE \n",
      "Monotherapy \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "% of Patients \n",
      "Diarrhea \n",
      "53.2 \n",
      "11.7 \n",
      "Nausea/Vomiting \n",
      "25.5 \n",
      "8.3 \n",
      "Flatulence \n",
      "12.1 \n",
      "5.5 \n",
      "Asthenia \n",
      "9.2 \n",
      "5.5 \n",
      "Indigestion \n",
      "7.1 \n",
      "4.1 \n",
      "Abdominal Discomfort \n",
      "6.4 \n",
      "4.8 \n",
      "Headache \n",
      "5.7 \n",
      "4.8 \n",
      "* Reactions that were more common in GLUCOPHAGE- than placebo-treated patients. \n",
      "Diarrhea led to discontinuation of study medication in 6% of patients treated with\n",
      "\n",
      "--- Chunk 68 ---\n",
      "997 6.4 \n",
      "4.8 \n",
      "Headache \n",
      "5.7 \n",
      "4.8 \n",
      "* Reactions that were more common in GLUCOPHAGE- than placebo-treated patients. \n",
      "Diarrhea led to discontinuation of study medication in 6% of patients treated with \n",
      "GLUCOPHAGE. Additionally, the following adverse reactions were reported in ≥1.0% to ≤5.0% \n",
      "of GLUCOPHAGE patients and were more commonly reported with GLUCOPHAGE than \n",
      "placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, \n",
      "sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation. \n",
      "In worldwide clinical trials over 900 patients with type 2 diabetes have been treated with \n",
      "GLUCOPHAGE XR in placebo- and active-controlled studies. In placebo-controlled trials, 781 \n",
      "patients were administered GLUCOPHAGE XR and 195 patients received placebo. Adverse \n",
      "reactions reported in greater than 5% of the GLUCOPHAGE XR patients, and that were more \n",
      "common in GLUCOPHAGE XR- than placebo-treated patients, are listed in Table 12. \n",
      "23\n",
      "\n",
      "--- Chunk 69 ---\n",
      "326 reactions reported in greater than 5% of the GLUCOPHAGE XR patients, and that were more \n",
      "common in GLUCOPHAGE XR- than placebo-treated patients, are listed in Table 12. \n",
      "23 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 70 ---\n",
      "976 Table 12: Most Common Adverse Reactions (>5.0 Percent) in Placebo-Controlled Studies \n",
      "of GLUCOPHAGE XR* \n",
      "Adverse Reaction \n",
      "GLUCOPHAGE XR \n",
      "(n=781) \n",
      "Placebo \n",
      "(n=195) \n",
      "% of Patients \n",
      "Diarrhea \n",
      "9.6 \n",
      "2.6 \n",
      "Nausea/Vomiting \n",
      "6.5 \n",
      "1.5 \n",
      "* Reactions that were more common in GLUCOPHAGE XR- than placebo-treated patients. \n",
      "Diarrhea led to discontinuation of study medication in 0.6% of patients treated with \n",
      "GLUCOPHAGE XR. Additionally, the following adverse reactions were reported in ≥1.0% to \n",
      "≤5.0% of GLUCOPHAGE XR patients and were more commonly reported with \n",
      "GLUCOPHAGE XR than placebo: abdominal pain, constipation, distention abdomen, \n",
      "dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste \n",
      "disturbance. \n",
      "Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with \n",
      "postmarketing use of metformin. \n",
      "Pediatric Patients \n",
      "In clinical trials with GLUCOPHAGE in pediatric patients with type 2 diabetes, the profile of\n",
      "\n",
      "--- Chunk 71 ---\n",
      "982 postmarketing use of metformin. \n",
      "Pediatric Patients \n",
      "In clinical trials with GLUCOPHAGE in pediatric patients with type 2 diabetes, the profile of \n",
      "adverse reactions was similar to that observed in adults. \n",
      "OVERDOSAGE \n",
      "Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than \n",
      "50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association \n",
      "with metformin hydrochloride has been established. Lactic acidosis has been reported in \n",
      "approximately 32% of metformin overdose cases (see WARNINGS). Metformin is dialyzable \n",
      "with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, \n",
      "hemodialysis may be useful for removal of accumulated drug from patients in whom metformin \n",
      "overdosage is suspected. \n",
      "DOSAGE AND ADMINISTRATION \n",
      "There is no fixed dosage regimen for the management of hyperglycemia in patients with type \n",
      "2 diabetes with GLUCOPHAGE or GLUCOPHAGE XR or any other pharmacologic agent.\n",
      "\n",
      "--- Chunk 72 ---\n",
      "610 DOSAGE AND ADMINISTRATION \n",
      "There is no fixed dosage regimen for the management of hyperglycemia in patients with type \n",
      "2 diabetes with GLUCOPHAGE or GLUCOPHAGE XR or any other pharmacologic agent. \n",
      "Dosage of GLUCOPHAGE or GLUCOPHAGE XR must be individualized on the basis of both \n",
      "effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The \n",
      "maximum recommended daily dose of GLUCOPHAGE is 2550 mg in adults and 2000 mg in \n",
      "24 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 73 ---\n",
      "929 pediatric patients (10-16 years of age); the maximum recommended daily dose of \n",
      "GLUCOPHAGE XR in adults is 2000 mg. \n",
      "GLUCOPHAGE should be given in divided doses with meals while GLUCOPHAGE XR should \n",
      "generally be given once daily with the evening meal. GLUCOPHAGE or GLUCOPHAGE XR \n",
      "should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side \n",
      "effects and to permit identification of the minimum dose required for adequate glycemic control \n",
      "of the patient. \n",
      "During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting \n",
      "plasma glucose should be used to determine the therapeutic response to GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and identify the minimum effective dose for the patient. Thereafter, \n",
      "glycosylated hemoglobin should be measured at intervals of approximately 3 months. The \n",
      "therapeutic goal should be to decrease both fasting plasma glucose and glycosylated\n",
      "\n",
      "--- Chunk 74 ---\n",
      "932 glycosylated hemoglobin should be measured at intervals of approximately 3 months. The \n",
      "therapeutic goal should be to decrease both fasting plasma glucose and glycosylated \n",
      "hemoglobin levels to normal or near normal by using the lowest effective dose of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR, either when used as monotherapy or in \n",
      "combination with sulfonylurea or insulin. \n",
      "Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary \n",
      "failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of \n",
      "medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after \n",
      "an initial period of effectiveness. \n",
      "Short-term administration of GLUCOPHAGE or GLUCOPHAGE XR may be sufficient during \n",
      "periods of transient loss of control in patients usually well-controlled on diet alone. \n",
      "GLUCOPHAGE XR tablets must be swallowed whole and never crushed or chewed.\n",
      "\n",
      "--- Chunk 75 ---\n",
      "983 periods of transient loss of control in patients usually well-controlled on diet alone. \n",
      "GLUCOPHAGE XR tablets must be swallowed whole and never crushed or chewed. \n",
      "Occasionally, the inactive ingredients of GLUCOPHAGE XR will be eliminated in the feces as a \n",
      "soft, hydrated mass. (See Patient Information printed below.) \n",
      "Recommended Dosing Schedule \n",
      "Adults \n",
      "The usual starting dose of GLUCOPHAGE Tablets is 500 mg twice a day or 850 mg once a day, \n",
      "given with meals.  In general, clinically significant responses are not seen at doses below 1500 \n",
      "mg per day.  Dosage increases should be made in increments of 500 mg weekly or 850 mg every \n",
      "2 weeks, up to a total of 2000 mg per day, given in divided doses. The dosage of \n",
      "GLUCOPHAGE must be individualized on the basis of both effectiveness and tolerability. \n",
      "Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For \n",
      "25 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "\n",
      "--- Chunk 76 ---\n",
      "252 Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For \n",
      "25 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 77 ---\n",
      "924 those patients requiring additional glycemic control, GLUCOPHAGE may be given to a \n",
      "maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given \n",
      "3 times a day with meals. \n",
      "The usual starting dose of GLUCOPHAGE XR (metformin hydrochloride) Extended-Release \n",
      "Tablets is 500 mg once daily with the evening meal.  In general, clinically significant responses \n",
      "are not seen at doses below 1500 mg per day.  Dosage increases should be made in increments of \n",
      "500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal. The dosage of \n",
      "GLUCOPHAGE XR must be individualized on the basis of both effectiveness and tolerability. If \n",
      "glycemic control is not achieved on GLUCOPHAGE XR 2000 mg once daily, a trial of \n",
      "GLUCOPHAGE XR 1000 mg twice daily should be considered. If higher doses of metformin \n",
      "are required, GLUCOPHAGE should be used at total daily doses up to 2550 mg administered in\n",
      "\n",
      "--- Chunk 78 ---\n",
      "977 GLUCOPHAGE XR 1000 mg twice daily should be considered. If higher doses of metformin \n",
      "are required, GLUCOPHAGE should be used at total daily doses up to 2550 mg administered in \n",
      "divided daily doses, as described above. (See CLINICAL PHARMACOLOGY: Clinical \n",
      "Studies.) \n",
      "Patients receiving GLUCOPHAGE treatment may be safely switched to GLUCOPHAGE XR \n",
      "once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from \n",
      "GLUCOPHAGE to GLUCOPHAGE XR, glycemic control should be closely monitored and \n",
      "dosage adjustments made accordingly (see CLINICAL PHARMACOLOGY: Clinical \n",
      "Studies). \n",
      "Pediatrics \n",
      "The usual starting dose of GLUCOPHAGE is 500 mg twice a day, given with meals. Dosage \n",
      "increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, \n",
      "given in divided doses. The dosage of GLUCOPHAGE must be individualized on the basis of \n",
      "both effectiveness and tolerability. Safety and effectiveness of GLUCOPHAGE XR in pediatric\n",
      "\n",
      "--- Chunk 79 ---\n",
      "935 given in divided doses. The dosage of GLUCOPHAGE must be individualized on the basis of \n",
      "both effectiveness and tolerability. Safety and effectiveness of GLUCOPHAGE XR in pediatric \n",
      "patients have not been established. \n",
      "Recommendations for Use in Renal Impairment \n",
      "Assess renal function prior to initiation of GLUCOPHAGE or GLUCOPHAGE XR and \n",
      "periodically thereafter. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR is contraindicated in patients with an estimated \n",
      "glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2 . \n",
      "Initiation of GLUCOPHAGE or GLUCOPHAGE XR in patients with an eGFR between 30 – 45 \n",
      "mL/minute/1.73 m2 is not recommended.  \n",
      "In patients taking GLUCOPHAGE or GLUCOPHAGE XR whose eGFR later falls below 45 \n",
      "mL/min/1.73 m2, assess the benefit risk of continuing therapy.  \n",
      "26 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 80 ---\n",
      "974 Discontinue GLUCOPHAGE or GLUCOPHAGE XR if the patient’s eGFR later falls below 30 \n",
      "mL/minute/1.73 m2 (See WARNINGS and PRECAUTIONS). \n",
      "Discontinuation for Iodinated Contrast Imaging Procedures \n",
      "Discontinue GLUCOPHAGE or GLUCOPHAGE XR at the time of, or prior to, an iodinated \n",
      "contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in \n",
      "patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be \n",
      "administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging \n",
      "procedure; restart GLUCOPHAGE or GLUCOPHAGE XR if renal function is stable. \n",
      "Concomitant GLUCOPHAGE or GLUCOPHAGE XR and Oral \n",
      "Sulfonylurea Therapy in Adult Patients \n",
      "If patients have not responded to 4 weeks of the maximum dose of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR monotherapy, consideration should be given to gradual addition of an oral \n",
      "sulfonylurea while continuing GLUCOPHAGE or GLUCOPHAGE XR at the maximum dose,\n",
      "\n",
      "--- Chunk 81 ---\n",
      "985 GLUCOPHAGE XR monotherapy, consideration should be given to gradual addition of an oral \n",
      "sulfonylurea while continuing GLUCOPHAGE or GLUCOPHAGE XR at the maximum dose, \n",
      "even if prior primary or secondary failure to a sulfonylurea has occurred. Clinical and \n",
      "pharmacokinetic drug-drug interaction data are currently available only for metformin plus \n",
      "glyburide (glibenclamide). \n",
      "With concomitant GLUCOPHAGE or GLUCOPHAGE XR and sulfonylurea therapy, the \n",
      "desired control of blood glucose may be obtained by adjusting the dose of each drug. In a clinical \n",
      "trial of patients with type 2 diabetes and prior failure on glyburide, patients started on \n",
      "GLUCOPHAGE 500 mg and glyburide 20 mg were titrated to 1000/20 mg, 1500/20 mg, \n",
      "2000/20 mg, or 2500/20 mg of GLUCOPHAGE and glyburide, respectively, to reach the goal of \n",
      "glycemic control as measured by FPG, HbA1c, and plasma glucose response (see CLINICAL \n",
      "PHARMACOLOGY: Clinical Studies). However, attempts should be made to identify the\n",
      "\n",
      "--- Chunk 82 ---\n",
      "946 glycemic control as measured by FPG, HbA1c, and plasma glucose response (see CLINICAL \n",
      "PHARMACOLOGY: Clinical Studies). However, attempts should be made to identify the \n",
      "minimum effective dose of each drug to achieve this goal. With concomitant GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and sulfonylurea therapy, the risk of hypoglycemia associated with \n",
      "sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken. \n",
      "(See Package Insert of the respective sulfonylurea.) \n",
      "If patients have not satisfactorily responded to 1 to 3 months of concomitant therapy with the \n",
      "maximum dose of GLUCOPHAGE or GLUCOPHAGE XR and the maximum dose of an oral \n",
      "sulfonylurea, consider therapeutic alternatives including switching to insulin with or without \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "27 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 83 ---\n",
      "935 Concomitant GLUCOPHAGE or GLUCOPHAGE XR and Insulin \n",
      "Therapy in Adult Patients \n",
      "The current insulin dose should be continued upon initiation of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR therapy. GLUCOPHAGE or GLUCOPHAGE XR therapy should be \n",
      "initiated at 500 mg once daily in patients on insulin therapy. For patients not responding \n",
      "adequately, the dose of GLUCOPHAGE or GLUCOPHAGE XR should be increased by 500 mg \n",
      "after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control \n",
      "is achieved. The maximum recommended daily dose is 2500 mg for GLUCOPHAGE and \n",
      "2000 mg for GLUCOPHAGE XR. It is recommended that the insulin dose be decreased by \n",
      "10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in \n",
      "patients receiving concomitant insulin and GLUCOPHAGE or GLUCOPHAGE XR. Further \n",
      "adjustment should be individualized based on glucose-lowering response. \n",
      "Specific Patient Populations\n",
      "\n",
      "--- Chunk 84 ---\n",
      "841 patients receiving concomitant insulin and GLUCOPHAGE or GLUCOPHAGE XR. Further \n",
      "adjustment should be individualized based on glucose-lowering response. \n",
      "Specific Patient Populations \n",
      "GLUCOPHAGE or GLUCOPHAGE XR are not recommended for use in pregnancy. \n",
      "GLUCOPHAGE is not recommended in patients below the age of 10 years. GLUCOPHAGE XR \n",
      "is not recommended in pediatric patients (below the age of 17 years). \n",
      "The initial and maintenance dosing of GLUCOPHAGE or GLUCOPHAGE XR should be \n",
      "conservative in patients with advanced age, due to the potential for decreased renal function in \n",
      "this population. Any dosage adjustment should be based on a careful assessment of renal \n",
      "function. \n",
      "28 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 85 ---\n",
      "984 HOW SUPPLIED \n",
      "GLUCOPHAGE® (metformin hydrochloride) Tablets \n",
      "500 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6060-05 \n",
      "500 mg \n",
      "Bottles of 500 \n",
      "NDC 0087-6060-10 \n",
      "850 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6070-05 \n",
      "1000 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6071-11 \n",
      "GLUCOPHAGE 500 mg tablets are round, white to off-white, film-coated tablets debossed with \n",
      "\"BMS 6060\" around the periphery of the tablet on one side and \"500\" debossed across the face of \n",
      "the other side. \n",
      "GLUCOPHAGE 850 mg tablets are round, white to off-white, film-coated tablets debossed with \n",
      "\"BMS 6070\" around the periphery of the tablet on one side and \"850\" debossed across the face of \n",
      "the other side. \n",
      "GLUCOPHAGE 1000 mg tablets are white, oval, biconvex, film-coated tablets with \"BMS \n",
      "6071\" debossed on one side and \"1000\" debossed on the opposite side and with a bisect line on \n",
      "both sides. \n",
      "GLUCOPHAGE® XR (metformin hydrochloride) Extended-Release Tablets \n",
      "500 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6063-13 \n",
      "750 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6064-13\n",
      "\n",
      "--- Chunk 86 ---\n",
      "967 both sides. \n",
      "GLUCOPHAGE® XR (metformin hydrochloride) Extended-Release Tablets \n",
      "500 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6063-13 \n",
      "750 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6064-13 \n",
      "GLUCOPHAGE XR 500 mg tablets are white to off-white, capsule shaped, biconvex tablets, \n",
      "with \"BMS 6063\" debossed on one side and \"500\" debossed across the face of the other side. \n",
      "GLUCOPHAGE XR 750 mg tablets are capsule shaped, biconvex tablets, with \"BMS 6064\" \n",
      "debossed on one side and \"750\" debossed on the other side. The tablets are pale red and may \n",
      "have a mottled appearance. \n",
      "Storage \n",
      "Store at 20°–25° C (68°–77° F); excursions permitted to 15°–30° C (59°–86° F). [See USP \n",
      "Controlled Room Temperature.] \n",
      "Dispense in light-resistant containers. \n",
      "GLUCOPHAGE® is a registered trademark of Merck Santé S.A.S., an associate of Merck KGaA of \n",
      "29 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 87 ---\n",
      "321 Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company. \n",
      "Distributed by: \n",
      "Bristol-Myers Squibb Company \n",
      "Princeton, NJ 08543 USA \n",
      "[print code] \n",
      "Rev April 2017 \n",
      "30 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 88 ---\n",
      "986 Patient Information \n",
      "GLUCOPHAGE® \n",
      "(metformin hydrochloride) Tablets \n",
      "and \n",
      "GLUCOPHAGE® XR \n",
      "(metformin hydrochloride) Extended-Release Tablets \n",
      "Read this information carefully before you start taking this medicine and each time you refill \n",
      "your prescription. There may be new information. This information does not take the place of \n",
      "your doctor’s advice. Ask your doctor or pharmacist if you do not understand some of this \n",
      "information or if you want to know more about this medicine. \n",
      "What are GLUCOPHAGE and GLUCOPHAGE XR? \n",
      "GLUCOPHAGE and GLUCOPHAGE XR are used to treat type 2 diabetes. This is also known \n",
      "as non-insulin-dependent diabetes mellitus. People with type 2 diabetes are not able to make \n",
      "enough insulin or respond normally to the insulin their bodies make. When this happens, sugar \n",
      "(glucose) builds up in the blood. This can lead to serious medical problems including kidney \n",
      "damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main\n",
      "\n",
      "--- Chunk 89 ---\n",
      "941 (glucose) builds up in the blood. This can lead to serious medical problems including kidney \n",
      "damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main \n",
      "goal of treating diabetes is to lower your blood sugar to a normal level. \n",
      "High blood sugar can be lowered by diet and exercise, by a number of medicines taken by \n",
      "mouth, and by insulin shots. Before you take GLUCOPHAGE or GLUCOPHAGE XR, try to \n",
      "control your diabetes by exercise and weight loss. While you take your diabetes medicine, \n",
      "continue to exercise and follow the diet advised for your diabetes. No matter what your \n",
      "recommended diabetes management plan is, studies have shown that maintaining good blood \n",
      "sugar control can prevent or delay complications of diabetes, such as blindness. \n",
      "GLUCOPHAGE and GLUCOPHAGE XR have the same active ingredient. However, \n",
      "GLUCOPHAGE XR works longer in your body. Both of these medicines help control your\n",
      "\n",
      "--- Chunk 90 ---\n",
      "861 GLUCOPHAGE and GLUCOPHAGE XR have the same active ingredient. However, \n",
      "GLUCOPHAGE XR works longer in your body. Both of these medicines help control your \n",
      "blood sugar in a number of ways. These include helping your body respond better to the insulin it \n",
      "makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of \n",
      "sugar your intestines absorb. GLUCOPHAGE and GLUCOPHAGE XR do not cause your body \n",
      "to make more insulin. Because of this, when taken alone, they rarely cause hypoglycemia (low \n",
      "blood sugar), and usually do not cause weight gain. However, when they are taken with a \n",
      "sulfonylurea or with insulin, hypoglycemia is more likely to occur, as is weight gain. \n",
      "31 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 91 ---\n",
      "917 Tell your doctor if you are pregnant or plan to become pregnant. GLUCOPHAGE and \n",
      "GLUCOPHAGE XR may not be right for you. Talk with your doctor about your choices. You \n",
      "should also discuss your choices with your doctor if you are nursing a child. \n",
      "Can GLUCOPHAGE or GLUCOPHAGE XR be used in children? \n",
      "GLUCOPHAGE has been shown to effectively lower glucose levels in children (ages 10-16 \n",
      "years) with type 2 diabetes. GLUCOPHAGE has not been studied in children younger than 10 \n",
      "years old. GLUCOPHAGE has not been studied in combination with other oral glucose-control \n",
      "medicines or insulin in children. If you have any questions about the use of GLUCOPHAGE in \n",
      "children, talk with your doctor or other healthcare provider. \n",
      "GLUCOPHAGE XR has not been studied in children. \n",
      "How should I take GLUCOPHAGE or GLUCOPHAGE XR? \n",
      "Your doctor will tell you how much medicine to take and when to take it. You will probably start\n",
      "\n",
      "--- Chunk 92 ---\n",
      "920 GLUCOPHAGE XR has not been studied in children. \n",
      "How should I take GLUCOPHAGE or GLUCOPHAGE XR? \n",
      "Your doctor will tell you how much medicine to take and when to take it. You will probably start \n",
      "out with a low dose of the medicine. Your doctor may slowly increase your dose until your blood \n",
      "sugar is better controlled. You should take GLUCOPHAGE or GLUCOPHAGE XR with meals. \n",
      "Your doctor may have you take other medicines along with GLUCOPHAGE or GLUCOPHAGE \n",
      "XR to control your blood sugar. These medicines may include insulin shots. Taking \n",
      "GLUCOPHAGE or GLUCOPHAGE XR with insulin may help you better control your blood \n",
      "sugar while reducing the insulin dose. \n",
      "Continue your exercise and diet program and test your blood sugar regularly while taking \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. Your doctor will monitor your diabetes and may \n",
      "perform blood tests on you from time to time to make sure your kidneys and your liver are\n",
      "\n",
      "--- Chunk 93 ---\n",
      "909 GLUCOPHAGE or GLUCOPHAGE XR. Your doctor will monitor your diabetes and may \n",
      "perform blood tests on you from time to time to make sure your kidneys and your liver are \n",
      "functioning normally. There is no evidence that GLUCOPHAGE or GLUCOPHAGE XR causes \n",
      "harm to the liver or kidneys. \n",
      "Tell your doctor if you: \n",
      "•  have an illness that causes severe vomiting, diarrhea or fever, or if you drink a much \n",
      "lower amount of liquid than normal. These conditions can lead to severe dehydration \n",
      "(loss of water in your body). You may need to stop taking GLUCOPHAGE or \n",
      "GLUCOPHAGE XR for a short time. \n",
      "•  plan to have surgery or an x-ray procedure with injection of dye (contrast agent). You \n",
      "may need to stop taking GLUCOPHAGE or GLUCOPHAGE XR for a short time. \n",
      "32 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 94 ---\n",
      "992 •  start to take other medicines or change how you take a medicine. GLUCOPHAGE and \n",
      "GLUCOPHAGE XR can affect how well other drugs work, and some drugs can affect \n",
      "how well GLUCOPHAGE and GLUCOPHAGE XR work. Some medicines may cause \n",
      "high blood sugar. \n",
      "GLUCOPHAGE XR must be swallowed whole and never crushed or chewed. Occasionally, \n",
      "the inactive ingredients of GLUCOPHAGE XR may be eliminated as a soft mass in your stool \n",
      "that may look like the original tablet; this is not harmful and will not affect the way \n",
      "GLUCOPHAGE XR works to control your diabetes. \n",
      "What should I avoid while taking GLUCOPHAGE or GLUCOPHAGE \n",
      "XR? \n",
      "Do not drink a lot of alcoholic drinks while taking GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "This means you should not binge drink for short periods, and you should not drink a lot of \n",
      "alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis. \n",
      "What are the side effects of GLUCOPHAGE and GLUCOPHAGE XR? \n",
      "•  Lactic \n",
      "acidosis. \n",
      "Metformin, \n",
      "the \n",
      "active\n",
      "\n",
      "--- Chunk 95 ---\n",
      "953 alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis. \n",
      "What are the side effects of GLUCOPHAGE and GLUCOPHAGE XR? \n",
      "•  Lactic \n",
      "acidosis. \n",
      "Metformin, \n",
      "the \n",
      "active \n",
      "ingredient \n",
      "in \n",
      "GLUCOPHAGE \n",
      "and \n",
      "GLUCOPHAGE XR, can cause a rare but serious condition called lactic acidosis (a \n",
      "buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical \n",
      "emergency and must be treated in the hospital. \n",
      "Call your doctor right away if you have any of the following symptoms, which could be signs of \n",
      "lactic acidosis: \n",
      "•  you feel cold in your hands or feet \n",
      "•  you feel dizzy or lightheaded \n",
      "•  you have a slow or irregular heartbeat \n",
      "•  you feel very weak or tired \n",
      "•  you have unusual (not normal) muscle pain \n",
      "•  you have trouble breathing \n",
      "•  you feel sleepy or drowsy \n",
      "•  you have stomach pains, nausea or vomiting \n",
      "Most people who have had lactic acidosis with metformin have other things that, combined with\n",
      "\n",
      "--- Chunk 96 ---\n",
      "423 •  you feel sleepy or drowsy \n",
      "•  you have stomach pains, nausea or vomiting \n",
      "Most people who have had lactic acidosis with metformin have other things that, combined with \n",
      "the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, \n",
      "33 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 97 ---\n",
      "973 because you have a higher chance for getting lactic acidosis with GLUCOPHAGE or \n",
      "GLUCOPHAGE XR if you: \n",
      "•  have severe kidney problems, or your kidneys are affected by certain x-ray tests that use \n",
      "injectable dye \n",
      "•  have liver problems \n",
      "•  drink alcohol very often, or drink a lot of alcohol in short-term \"binge\" drinking \n",
      "•  get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a \n",
      "fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity \n",
      "or exercise and do not drink enough fluids \n",
      "•  have surgery \n",
      "•  have a heart attack, severe infection, or stroke \n",
      "The best way to keep from having a problem with lactic acidosis from metformin is to tell your \n",
      "doctor if you have any of the problems in the list above. Your doctor may decide to stop your \n",
      "GLUCOPHAGE or GLUCOPHAGE XR for a while if you have any of these things. \n",
      "Other Side Effects. Common side effects of GLUCOPHAGE and GLUCOPHAGE XR include\n",
      "\n",
      "--- Chunk 98 ---\n",
      "978 GLUCOPHAGE or GLUCOPHAGE XR for a while if you have any of these things. \n",
      "Other Side Effects. Common side effects of GLUCOPHAGE and GLUCOPHAGE XR include \n",
      "diarrhea, nausea, and upset stomach. These side effects generally go away after you take the \n",
      "medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell \n",
      "your doctor if the side effects bother you a lot, last for more than a few weeks, come back after \n",
      "they’ve gone away, or start later in therapy. You may need a lower dose or need to stop taking \n",
      "the medicine for a short period or for good. \n",
      "About 3 out of every 100 people who take GLUCOPHAGE or GLUCOPHAGE XR have an \n",
      "unpleasant metallic taste when they start taking the medicine. It lasts for a short time. \n",
      "GLUCOPHAGE and GLUCOPHAGE XR rarely cause hypoglycemia (low blood sugar) by \n",
      "themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol, \n",
      "or if you take other medicines to lower blood sugar.\n",
      "\n",
      "--- Chunk 99 ---\n",
      "821 themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol, \n",
      "or if you take other medicines to lower blood sugar. \n",
      "General advice about prescription medicines \n",
      "If you have questions or problems, talk with your doctor or other healthcare provider. You can \n",
      "ask your doctor or pharmacist for the information about GLUCOPHAGE and GLUCOPHAGE \n",
      "XR that is written for healthcare professionals. Medicines are sometimes prescribed for purposes \n",
      "other than those listed in a patient information leaflet. Do not use GLUCOPHAGE or \n",
      "GLUCOPHAGE XR for a condition for which it was not prescribed. Do not share your medicine \n",
      "with other people. \n",
      "34 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n",
      "--- Chunk 100 ---\n",
      "481 GLUCOPHAGE® is a registered trademark of Merck Santé S.A.S., an associate of Merck KGaA \n",
      "of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company. \n",
      "Other brands listed are the trademarks of their respective owners. \n",
      "Distributed by: \n",
      "Bristol-Myers Squibb Company \n",
      "Princeton, NJ 08543 USA \n",
      "[print code] \n",
      "Rev April 2017 \n",
      "35 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "\n"
     ]
    }
   ],
   "source": [
    "chunks = chunk_pages(pages)\n",
    "for i, chunk in enumerate(chunks, 1):\n",
    "    print(f\"--- Chunk {i} ---\")\n",
    "    print(len(chunk),chunk)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f0675f57",
   "metadata": {},
   "source": [
    "### Making the embeddings of the the labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "cb91def9",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/aaron/Desktop/FragRag/.venv/lib/python3.12/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unique labels: ['CARDINAL', 'DATE', 'GPE', 'LAW', 'LOC', 'NORP', 'ORDINAL', 'ORG', 'PERCENT', 'PERSON', 'PRODUCT', 'QUANTITY', 'TIME', 'WORK_OF_ART']\n",
      "FAISS index and label mapping saved.\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import faiss\n",
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer\n",
    "import pickle\n",
    "\n",
    "# --- 1. Load entities.json ---\n",
    "with open(\"entities.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)\n",
    "\n",
    "# --- 2. Extract unique labels ---\n",
    "labels = sorted({ent[\"label\"] for page in data for ent in page[\"entities\"]})\n",
    "print(\"Unique labels:\", labels)\n",
    "\n",
    "# --- 3. Load embedding model ---\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")  # Small, fast model\n",
    "\n",
    "# --- 4. Create embeddings ---\n",
    "embeddings = model.encode(labels, convert_to_numpy=True, normalize_embeddings=True)\n",
    "\n",
    "# --- 5. Create FAISS index ---\n",
    "dim = embeddings.shape[1]\n",
    "index = faiss.IndexFlatL2(dim)\n",
    "index.add(embeddings)\n",
    "\n",
    "# --- 6. Save FAISS index ---\n",
    "faiss.write_index(index, \"labels.index\")\n",
    "\n",
    "# --- 7. Also save mapping from index to labels ---\n",
    "with open(\"labels_mapping.pkl\", \"wb\") as f:\n",
    "    pickle.dump(labels, f)\n",
    "\n",
    "print(\"FAISS index and label mapping saved.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "907bd44e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total unique entity texts: 563\n",
      "FAISS index for entity texts saved.\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import faiss\n",
    "import numpy as np\n",
    "import pickle\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "# --- Load entities.json ---\n",
    "with open(\"entities.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    data = json.load(f)\n",
    "\n",
    "# --- Extract unique text values ---\n",
    "unique_texts = sorted({ent[\"text\"].strip() for page in data for ent in page[\"entities\"]})\n",
    "\n",
    "print(f\"Total unique entity texts: {len(unique_texts)}\")\n",
    "\n",
    "# --- Load embedding model ---\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "# --- Create normalized embeddings ---\n",
    "embeddings = model.encode(unique_texts, convert_to_numpy=True, normalize_embeddings=True)\n",
    "\n",
    "# --- Create FAISS cosine similarity index ---\n",
    "dim = embeddings.shape[1]\n",
    "index = faiss.IndexFlatIP(dim)  # Cosine similarity with normalized vectors\n",
    "index.add(embeddings)\n",
    "\n",
    "# --- Save index and mapping ---\n",
    "faiss.write_index(index, \"entity_texts_cosine.index\")\n",
    "with open(\"entity_texts_mapping.pkl\", \"wb\") as f:\n",
    "    pickle.dump(unique_texts, f)\n",
    "\n",
    "print(\"FAISS index for entity texts saved.\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3e1b33c7",
   "metadata": {},
   "source": [
    "### Searching the Faiss"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d30be20e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Twice Daily \n",
      "GLUCOPHAGE XR \n",
      "1000 -> 0.5015\n",
      "358 L. Metformin -> 0.4670\n",
      "600 mg/kg -> 0.4543\n",
      "45 mL/min/1.73 m2 -> 0.4325\n",
      "Metformin -> 0.4306\n",
      "mL. Metformin -> 0.4291\n",
      "GLUCOPHAGE -> 0.4197\n",
      "60 mL -> 0.3668\n",
      "Gender \n",
      "Metformin -> 0.3663\n",
      "Total Triglycerides -> 0.3614\n",
      "Dosage -> 0.3463\n",
      "DOSAGE -> 0.3463\n",
      "30 mL -> 0.3352\n",
      "50 grams -> 0.3273\n",
      "mcg/mL -> 0.3174\n",
      "Plasma Glucose -> 0.3143\n",
      "Serum Lipid \n",
      "Variables -> 0.3094\n",
      "https://www.fda.gov/drugsatfda -> 0.2962\n",
      "HDL-Cholesterol -> 0.2759\n",
      "Insulin Dose -> 0.2659\n",
      "GLU -> 0.2565\n",
      "Hemoglobin A1c -> 0.2547\n",
      "LDL-Cholesterol -> 0.2527\n",
      "Drug Interactions -> 0.2470\n",
      "serum creatinine -> 0.2396\n",
      "CLINICAL PHARMACOLOGY -> 0.2247\n",
      "9.6 \n",
      "2.6 \n",
      "Nausea/Vomiting \n",
      "6.5 \n",
      "1.5 -> 0.2213\n",
      "Once Daily \n",
      "Hemoglobin A1c -> 0.2159\n",
      "Placebo/Insulin Summary -> 0.1946\n",
      "Bristol-Myers Squibb Company -> 0.1914\n"
     ]
    }
   ],
   "source": [
    "# --- Load index and mapping ---\n",
    "index = faiss.read_index(\"entity_texts_cosine.index\")\n",
    "with open(\"entity_texts_mapping.pkl\", \"rb\") as f:\n",
    "    unique_texts = pickle.load(f)\n",
    "\n",
    "# --- Load embedding model ---\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "# --- Query ---\n",
    "query = \"\"\"916 in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is \n",
    "12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. \n",
    "GLUCOPHAGE tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Each \n",
    "tablet contains the inactive ingredients povidone and magnesium stearate. In addition, the coating \n",
    "for the 500 mg and 850 mg tablets contains hypromellose and the coating for the 1000 mg tablet \n",
    "contains hypromellose and polyethylene glycol. \n",
    "GLUCOPHAGE XR contains 500 mg or 750 mg of metformin hydrochloride as the active \n",
    "ingredient.\"\"\"\n",
    "embedding = model.encode([query], convert_to_numpy=True, normalize_embeddings=True)\n",
    "\n",
    "# --- Search ---\n",
    "similarities, indices = index.search(embedding, k=30)\n",
    "results = [(unique_texts[idx], float(sim)) for idx, sim in zip(indices[0], similarities[0])]\n",
    "\n",
    "# --- Sort descending (already sorted by FAISS) ---\n",
    "for text, sim in results:\n",
    "    print(f\"{text} -> {sim:.4f}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c7e02d3d",
   "metadata": {},
   "source": [
    "### Building Relationships"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "a991e557",
   "metadata": {},
   "outputs": [],
   "source": [
    "import faiss\n",
    "import pickle\n",
    "import json\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "def build_relationships_for_chunks(chunks, k=30, save_path=\"relationships.json\"):\n",
    "    # --- Load FAISS index and mapping ---\n",
    "    index = faiss.read_index(\"entity_texts_cosine.index\")\n",
    "    with open(\"entity_texts_mapping.pkl\", \"rb\") as f:\n",
    "        unique_texts = pickle.load(f)\n",
    "\n",
    "    # --- Load embedding model ---\n",
    "    model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "    all_relationships = []\n",
    "\n",
    "    for chunk in chunks:\n",
    "        # Get relevant entities from FAISS\n",
    "        embedding = model.encode([chunk], convert_to_numpy=True, normalize_embeddings=True)\n",
    "        similarities, indices = index.search(embedding, k=k)\n",
    "        results = [unique_texts[idx] for idx in indices[0]]\n",
    "\n",
    "        # Prepare the prompt\n",
    "        prompt = f\"\"\"\n",
    "You are an expert in knowledge graph extraction.\n",
    "Given the following text chunk and list of relevant entities, \n",
    "return ONLY a valid JSON array describing entity relationships found in the chunk.\n",
    "No explanations, no commentary — ONLY the JSON array.\n",
    "Format:\n",
    "[\n",
    "  {{\"source\": \"<entity1>\", \"relationship\": \"<relation>\", \"target\": \"<entity2>\"}}\n",
    "]\n",
    "\n",
    "Text chunk:\n",
    "\\\"\\\"\\\"{chunk}\\\"\\\"\\\"\n",
    "\n",
    "Relevant entities:\n",
    "{results}\n",
    "\n",
    "Respond with the JSON array only.\n",
    "\"\"\"\n",
    "\n",
    "        llm_output = ask_ollama(prompt).strip()  # Uses your already defined ask_ollama()\n",
    "\n",
    "        try:\n",
    "            relationships = json.loads(llm_output)\n",
    "            if isinstance(relationships, list):\n",
    "                all_relationships.extend(relationships)\n",
    "            else:\n",
    "                print(\"⚠️ LLM returned JSON but not a list:\", llm_output)\n",
    "        except json.JSONDecodeError:\n",
    "            print(\"❌ JSON parse error. LLM output was:\")\n",
    "            print(llm_output)\n",
    "\n",
    "        # Save progress after each chunk\n",
    "        with open(save_path, \"w\", encoding=\"utf-8\") as f:\n",
    "            json.dump(all_relationships, f, ensure_ascii=False, indent=2)\n",
    "\n",
    "    return all_relationships\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "1eb25a24",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "❌ JSON parse error. LLM output was:\n",
      "[\n",
      "  {\"source\": \"Metformin\", \"relationship\": \"associated\", \"target\": \"lactic acidosis\"},\n",
      "  {\"source\": \"Renal Impairment\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"topiramate\", \"relationship\": \"concomitant use\", \"target\": \"metformin\"},\n",
      "  {\"source\": \"age 65 years old or greater\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"surgery and other procedures\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"hypoxic states (e.g., acute congestive heart failure)\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"excessive alcohol intake\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"hepatic impairment\", \"relationship\": \"risk factor\", \"target\": \"metformin-associated lactic acidosis\"}\n",
      "❌ JSON parse error. LLM output was:\n",
      "[\n",
      "  {\"source\": \"Metformin\", \"relationship\": \"increases risk of\", \"target\": \"lactic acidosis\"},\n",
      "  {\"source\": \"Age 65 or greater\", \"relationship\": \"associated with increased risk of\", \"target\": \"metformin-associated lactic acidosis\"},\n",
      "  {\"source\": \"Elderly patients\", \"relationship\": \"have a greater likelihood of having\", \"target\": \"hepatic, renal, or cardiac impairment\"},\n",
      "  {\"source\": \"Renal function\", \"relationship\": \"impairs\", \"target\": \"Metformin\"},\n",
      "  {\"source\": \"Radiologic studies with contrast\", \"relationship\": \"leads to an acute decrease in\", \"target\": \"renal function\"},\n",
      "  {\"source\": \"metformin-treated patients\", \"relationship\": \"occurrence of lactic acidosis\", \"target\": \"Renal Impairment\"}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'source': 'GLUCOPHAGE', 'relationship': 'relatedTo', 'target': 'Metformin'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'hasFormula',\n",
       "  'target': 'C4H11N5 • HCl'},\n",
       " {'source': 'metformin', 'relationship': 'contains', 'target': 'povidone'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'contains',\n",
       "  'target': 'magnesium stearate'},\n",
       " {'source': 'GLUCOPHAGE tablets',\n",
       "  'relationship': 'contain',\n",
       "  'target': 'metformin hydrochloride'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'contain',\n",
       "  'target': 'metformin hydrochloride'},\n",
       " {'source': 'sodium carboxymethyl cellulose',\n",
       "  'relationship': 'ingredient',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'hypromellose',\n",
       "  'relationship': 'ingredient',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'magnesium stearate',\n",
       "  'relationship': 'ingredient',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'metformin hydrochloride',\n",
       "  'relationship': 'component',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'polymer matrix system',\n",
       "  'relationship': 'component',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'improves',\n",
       "  'target': 'glucose tolerance'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'decreases',\n",
       "  'target': 'hepatic glucose production'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'decreases',\n",
       "  'target': 'intestinal absorption of glucose'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'increases',\n",
       "  'target': 'peripheral glucose uptake'},\n",
       " {'source': 'Metformin', 'relationship': 'utilizes', 'target': 'glucose'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'absorption',\n",
       "  'target': 'plasma concentration'},\n",
       " {'source': 'food',\n",
       "  'relationship': 'decreases',\n",
       "  'target': 'extent of absorption'},\n",
       " {'source': 'food',\n",
       "  'relationship': 'slightly delays',\n",
       "  'target': 'time to peak plasma concentration'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'decreased absorption',\n",
       "  'target': 'increasing doses'},\n",
       " {'source': 'Metformin', 'relationship': '', 'target': ''},\n",
       " {'source': 'FDA', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'similar extent of absorption',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'less than dose proportional',\n",
       "  'target': 'once daily doses'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'peak plasma levels',\n",
       "  'target': '2000 mg once-daily doses'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'administered',\n",
       "  'target': 'metformin'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'partitioned into',\n",
       "  'target': 'erythrocytes'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'partitions',\n",
       "  'target': 'erythrocytes'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'doses', 'target': 'metformin'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'plasma levels',\n",
       "  'target': '<1 µg/mL'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'maximum doses',\n",
       "  'target': '5 µg/mL'},\n",
       " {'source': 'metformin', 'relationship': 'excreted', 'target': 'urine'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'elimination',\n",
       "  'target': 'renal route'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'absorption',\n",
       "  'target': 'oral administration'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'excretion',\n",
       "  'target': 'biliary excretion'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'clearance',\n",
       "  'target': 'renal clearance'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'half-life',\n",
       "  'target': 'plasma elimination half-life'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'half-life',\n",
       "  'target': 'blood elimination half-life'},\n",
       " {'source': 'Renal Impairment',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Metformin'},\n",
       " {'source': 'Hepatic Impairment',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Metformin'},\n",
       " {'source': 'Geriatrics',\n",
       "  'relationship': 'affected by',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'is decreased',\n",
       "  'target': 'total plasma clearance'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'is prolonged',\n",
       "  'target': 'half-life'},\n",
       " {'source': 'Metformin', 'relationship': 'is increased', 'target': 'Cmax'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'dosea',\n",
       "  'target': 'healthy, nondiabetic adults'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'dosea',\n",
       "  'target': 'adults with type 2 diabetes'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'dosea',\n",
       "  'target': 'elderly, healthy nondiabetic adults'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'dosea',\n",
       "  'target': 'renal-impaired adults'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'mentioned in',\n",
       "  'target': 'Pediatrics'},\n",
       " {'source': 'CLcr',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'creatinine clearance'},\n",
       " {'source': 'Gender', 'relationship': 'related_to', 'target': 'Metformin'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'does_not_differ_significantly',\n",
       "  'target': 'patients with type 2 diabetes'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'antihyperglycemic effect',\n",
       "  'target': 'Plasma Glucose'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'comparable in', 'target': 'whites'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'comparable in', 'target': 'blacks'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'comparable in',\n",
       "  'target': 'Hispanics'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Placebo'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Plasma Glucose'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Hemoglobin A1c'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Body Weight'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used in combination with',\n",
       "  'target': 'glyburide'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'dose adjusted by',\n",
       "  'target': '500 mg'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'taken by', 'target': 'patients'},\n",
       " {'source': 'metformin', 'relationship': 'taken by', 'target': 'patients'},\n",
       " {'source': 'glyburide', 'relationship': 'taken by', 'target': 'patients'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used in combination with',\n",
       "  'target': 'glyburide'},\n",
       " {'source': 'Fasting Plasma Glucose',\n",
       "  'relationship': 'Change at FINAL VISIT',\n",
       "  'target': '-63.5'},\n",
       " {'source': 'Hemoglobin A1c',\n",
       "  'relationship': 'Change at FINAL VISIT',\n",
       "  'target': '-1.7'},\n",
       " {'source': 'Body Weight',\n",
       "  'relationship': 'Change at FINAL VISIT',\n",
       "  'target': '0.9'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'lowered',\n",
       "  'target': 'mean fasting serum triglycerides'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'lowered',\n",
       "  'target': 'total cholesterol'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'lowered',\n",
       "  'target': 'LDL cholesterol'},\n",
       " {'source': 'Patients with type 2 diabetes',\n",
       "  'relationship': 'experienced',\n",
       "  'target': 'greater declines in plasma glucose and glycosylated hemoglobin'},\n",
       " {'source': 'FDA',\n",
       "  'relationship': 'relatedTo',\n",
       "  'target': 'https://www.fda.gov/drugsatfda'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'vs', 'target': 'Placebo'},\n",
       " {'source': 'GLUCOPHAGE/Glyburide',\n",
       "  'relationship': 'vs',\n",
       "  'target': 'Monotherapy'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'tended to remain stable or even decrease somewhat',\n",
       "  'target': 'Body Weight'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'plus insulin', 'target': 'insulin'},\n",
       " {'source': 'GLUCOPHAGE plus insulin',\n",
       "  'relationship': 'achieved a reduction',\n",
       "  'target': 'Hemoglobin A1c'},\n",
       " {'source': 'GLUCOPHAGE plus insulin',\n",
       "  'relationship': 'compared to',\n",
       "  'target': 'insulin plus placebo'},\n",
       " {'source': 'GLUCOPHAGE plus insulin',\n",
       "  'relationship': 'achieved at the final study visit with',\n",
       "  'target': '16% less insulin'},\n",
       " {'source': 'Table 5',\n",
       "  'relationship': 'relatedTo',\n",
       "  'target': 'Placebo-Controlled Studies'},\n",
       " {'source': 'GLUCOPHAGE/Insulin',\n",
       "  'relationship': 'comparedTo',\n",
       "  'target': 'Placebo/Insulin'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'relatedTo', 'target': 'Placebo'},\n",
       " {'source': 'Basline', 'relationship': 'relatedTo', 'target': 'FINAL VISIT'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'maintained',\n",
       "  'target': 'glycemic control'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'resulted in',\n",
       "  'target': 'reduction in body weight'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'taken with',\n",
       "  'target': 'evening meal'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Once Daily'},\n",
       " {'source': 'Placebo', 'relationship': '', 'target': 'Patients'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Patients'},\n",
       " {'source': 'Placebo', 'relationship': '', 'target': 'Placebo group'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': '',\n",
       "  'target': 'patients treated with GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'compared with',\n",
       "  'target': 'placebo group'},\n",
       " {'source': 'Twice Daily',\n",
       "  'relationship': 'taken with',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'once daily with meals',\n",
       "  'target': 'evening meal'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'twice daily with meals',\n",
       "  'target': 'meals'},\n",
       " {'source': 'Placebo',\n",
       "  'relationship': 'control group',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'HbA1c',\n",
       "  'relationship': 'change from baseline',\n",
       "  'target': 'final visit'},\n",
       " {'source': 'Placebo',\n",
       "  'relationship': 'Comparison',\n",
       "  'target': 'GLUCOPHAGE XR Extended-Release Tablets'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'Treatment',\n",
       "  'target': 'Glycemic Control'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'taken', 'target': 'twice daily'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'taken', 'target': 'evening meal'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': 'taken', 'target': 'once daily'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'dose', 'target': '500 mg'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'dose', 'target': 'twice daily'},\n",
       " {'source': 'study',\n",
       "  'relationship': 'conducted',\n",
       "  'target': 'patients with type 2 diabetes'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': ''},\n",
       " {'source': 'Twice Daily \\nGLUCOPHAGE XR \\n1000',\n",
       "  'relationship': '',\n",
       "  'target': ''},\n",
       " {'source': 'Once Daily', 'relationship': '', 'target': 'Hemoglobin A1c'},\n",
       " {'source': 'Plasma Glucose', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'treats',\n",
       "  'target': 'Hemoglobin A1c'},\n",
       " {'source': 'Twice Daily\\nGLUCOPHAGE XR\\n1000',\n",
       "  'relationship': 'dose',\n",
       "  'target': 'Hemoglobin A1c'},\n",
       " {'source': 'Total Cholesterol',\n",
       "  'relationship': 'has_mean_percent_change_at_final_visit',\n",
       "  'target': 'Baseline'},\n",
       " {'source': 'Total Triglycerides',\n",
       "  'relationship': 'has_mean_percent_change_at_final_visit',\n",
       "  'target': 'Baseline'},\n",
       " {'source': 'LDL-Cholesterol',\n",
       "  'relationship': 'has_mean_percent_change_at_final_visit',\n",
       "  'target': 'Baseline'},\n",
       " {'source': 'HDL-Cholesterol',\n",
       "  'relationship': 'has_mean_percent_change_at_final_visit',\n",
       "  'target': 'Baseline'},\n",
       " {'source': 'HDL-Cholesterol', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': ''},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'relatedTo',\n",
       "  'target': 'Total Cholesterol'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'relatedTo',\n",
       "  'target': 'Twice Daily \\nTotal Cholesterol'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'treats',\n",
       "  'target': 'Type 2 diabetes'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'compared to', 'target': 'Placebo'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'results in',\n",
       "  'target': 'Significant mean net reduction in FPG'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'indicated as an adjunct to',\n",
       "  'target': 'diet and exercise'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'indicated for use in',\n",
       "  'target': 'adults and children with type 2 diabetes mellitus'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'contraindicated in patients with',\n",
       "  'target': 'Severe renal impairment'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'contraindicated in patients with',\n",
       "  'target': 'Known hypersensitivity to metformin hydrochloride'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'contraindicated in patients with',\n",
       "  'target': 'Acute or chronic metabolic acidosis'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'associated',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'discontinue',\n",
       "  'target': 'metformin-associated lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'discontinue',\n",
       "  'target': 'metformin-associated lactic acidosis'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'decreases',\n",
       "  'target': 'liver uptake of lactate'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'increasing',\n",
       "  'target': 'lactate blood levels'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'relatedTo', 'target': 'metformin'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'relatedTo',\n",
       "  'target': 'metformin'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'associatedWith',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'Renal', 'relationship': 'associated_with', 'target': 'Metformin'},\n",
       " {'source': 'Renal Impairment',\n",
       "  'relationship': 'risk_factor_for',\n",
       "  'target': 'metformin-associated lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'contraindicated',\n",
       "  'target': 'patients with an eGFR less than 30 mL/min/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'patients with eGFR between 30-45 mL/min/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'contraindicated',\n",
       "  'target': 'patients with an eGFR less than 30 mL/min/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'patients with eGFR between 30-45 mL/min/1.73 m2'},\n",
       " {'source': 'specific drugs',\n",
       "  'relationship': 'may increase the risk of metformin-associated lactic acidosis',\n",
       "  'target': 'GLUCOPHAGE or GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'Discontinue',\n",
       "  'target': 'Iodinated Contrast Imaging Procedures'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'Restart',\n",
       "  'target': 'Renal Function'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'associated_with',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'potentiated_by',\n",
       "  'target': 'alcohol'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'discontinued_during',\n",
       "  'target': 'cardiovascular collapse (shock)'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'discontinued_during',\n",
       "  'target': 'acute myocardial infarction'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'discontinued_during',\n",
       "  'target': 'sepsis'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'used in', 'target': 'patients'},\n",
       " {'source': 'Vitamin B12',\n",
       "  'relationship': 'interference with absorption',\n",
       "  'target': 'B12-intrinsic factor complex'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'associated with',\n",
       "  'target': 'decrease in vitamin B12 levels'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': 'advised', 'target': 'patients'},\n",
       " {'source': 'vitamin B12',\n",
       "  'relationship': 'predisposed to developing',\n",
       "  'target': 'subnormal levels'},\n",
       " {'source': 'routine serum vitamin B12 measurements',\n",
       "  'relationship': 'may be useful',\n",
       "  'target': 'certain individuals'},\n",
       " {'source': 'Elderly',\n",
       "  'relationship': 'susceptible to',\n",
       "  'target': 'hypoglycemic effects'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'antidiabetic drug',\n",
       "  'target': None},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be informed of',\n",
       "  'target': 'potential risks and benefits'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be informed about',\n",
       "  'target': 'adherence to dietary instructions'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be informed about',\n",
       "  'target': 'regular exercise program'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be informed about',\n",
       "  'target': 'regular testing of blood glucose'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'is related to',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'patients',\n",
       "  'relationship': 'should be advised to',\n",
       "  'target': 'discontinue GLUCOPHAGE or GLUCOPHAGE XR'},\n",
       " {'source': 'patients',\n",
       "  'relationship': 'should be counseled against',\n",
       "  'target': 'excessive alcohol intake'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be counseled against',\n",
       "  'target': 'excessive alcohol intake'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'does not usually cause',\n",
       "  'target': 'hypoglycemia'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'may occur when used in conjunction with',\n",
       "  'target': 'oral sulfonylureas and insulin'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'should be informed that',\n",
       "  'target': 'GLUCOPHAGE XR must be swallowed whole'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Plasma Glucose'},\n",
       " {'source': 'Hemoglobin A1c',\n",
       "  'relationship': 'monitored by',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'serum creatinine',\n",
       "  'relationship': 'monitored by',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'Vitamin B12',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'megaloblastic anemia'},\n",
       " {'source': 'Vitamin B12',\n",
       "  'relationship': 'deficiency',\n",
       "  'target': 'should be excluded'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'may be required',\n",
       "  'target': 'renal function has been confirmed to be normal'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'pharmacokinetics or pharmacodynamics',\n",
       "  'target': 'glyburide'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'interacts with',\n",
       "  'target': 'Furosemide'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'increases',\n",
       "  'target': 'plasma and blood Cmax'},\n",
       " {'source': 'Furosemide', 'relationship': '', 'target': 'Renal'},\n",
       " {'source': 'Nifedipine', 'relationship': 'enhance', 'target': 'Metformin'},\n",
       " {'source': 'Cimetidine', 'relationship': 'interact', 'target': 'Metformin'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'may increase',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'increase',\n",
       "  'target': 'peak metformin plasma and whole blood concentrations'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'increase',\n",
       "  'target': 'plasma and whole blood metformin AUC'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'has no effect on',\n",
       "  'target': 'cimetidine pharmacokinetics'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'not affected when coadministered with',\n",
       "  'target': 'propranolol'},\n",
       " {'source': 'Metformin', 'relationship': 'interacts', 'target': 'salicylates'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'interacts',\n",
       "  'target': 'sulfonamides'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'interacts',\n",
       "  'target': 'chloramphenicol'},\n",
       " {'source': 'Metformin', 'relationship': 'interacts', 'target': 'probenecid'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'does not interact',\n",
       "  'target': 'sulfonylureas'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be observed for loss of blood glucose control',\n",
       "  'target': 'drugs that tend to produce hyperglycemia'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'should be observed for hypoglycemia when drugs are withdrawn',\n",
       "  'target': 'drugs that tend to produce hyperglycemia'},\n",
       " {'source': 'Topiramate',\n",
       "  'relationship': 'cause',\n",
       "  'target': 'decrease in serum bicarbonate'},\n",
       " {'source': 'acetazolamide or dichlorphenamide',\n",
       "  'relationship': 'cause',\n",
       "  'target': 'non-anion gap, hyperchloremic metabolic acidosis'},\n",
       " {'source': 'these drugs',\n",
       "  'relationship': 'may increase the risk for',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'potentiate the effect of',\n",
       "  'target': 'lactate metabolism'},\n",
       " {'source': 'Alcohol',\n",
       "  'relationship': 'potentiate the effect of',\n",
       "  'target': 'metformin on lactate metabolism'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'receive', 'target': 'Metformin'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': 'receive', 'target': 'Metformin'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'associated with',\n",
       "  'target': 'abnormal blood glucose levels during pregnancy'},\n",
       " {'source': 'Insulin',\n",
       "  'relationship': 'used',\n",
       "  'target': 'to maintain blood glucose levels as close to normal as possible'},\n",
       " {'source': 'Insulin', 'relationship': 'used', 'target': 'pregnancy'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should not be used',\n",
       "  'target': 'pregnancy'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'not teratogenic',\n",
       "  'target': 'rats and rabbits'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be considered',\n",
       "  'target': 'insulin therapy'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'discontinued', 'target': 'nursing'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'discontinued',\n",
       "  'target': 'the drug'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Pediatric'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used in',\n",
       "  'target': 'ages 10 to 16 years'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'recommended daily dose of',\n",
       "  'target': '2000 mg'},\n",
       " {'source': 'Elderly',\n",
       "  'relationship': 'respond differently from',\n",
       "  'target': 'younger patients'},\n",
       " {'source': 'Elderly',\n",
       "  'relationship': 'have decreased hepatic, renal, or cardiac function',\n",
       "  'target': None},\n",
       " {'source': 'Elderly',\n",
       "  'relationship': 'have concomitant disease or other drug therapy',\n",
       "  'target': None},\n",
       " {'source': 'Elderly',\n",
       "  'relationship': 'are at higher risk of lactic acidosis',\n",
       "  'target': None},\n",
       " {'source': 'Elderly patients',\n",
       "  'relationship': 'should have their renal function assessed more frequently',\n",
       "  'target': None},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'more common in',\n",
       "  'target': 'Placebo'},\n",
       " {'source': 'Diarrhea',\n",
       "  'relationship': 'led to discontinuation of study medication',\n",
       "  'target': 'patients treated with GLUCOPHAGE'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'reported in', 'target': 'Diarrhea'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'led to discontinuation of study medication in',\n",
       "  'target': 'study medication'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'more commonly reported with',\n",
       "  'target': 'placebo'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'reported in greater than',\n",
       "  'target': 'reactions'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Diarrhea'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Nausea/Vomiting'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': '',\n",
       "  'target': 'Cholestatic, hepatocellular, and mixed hepatocellular liver injury'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': '',\n",
       "  'target': 'Pediatric Patients'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'used for treatment of',\n",
       "  'target': 'Type 2 Diabetes'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'similar adverse reactions in pediatric patients',\n",
       "  'target': 'Adults'},\n",
       " {'source': 'Metformin hydrochloride',\n",
       "  'relationship': 'associated with',\n",
       "  'target': 'Lactic acidosis'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'dialyzable with clearance of up to',\n",
       "  'target': '170 mL/min'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'Dosage of',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'DOSAGE',\n",
       "  'relationship': 'must be individualized on the basis of',\n",
       "  'target': 'effectiveness and tolerance'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be given',\n",
       "  'target': 'meals'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'should be given',\n",
       "  'target': 'evening meal'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be started at a low dose, with gradual dose escalation',\n",
       "  'target': 'patient'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'should be used to determine the therapeutic response',\n",
       "  'target': 'plasma glucose'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'should be used to identify the minimum effective dose',\n",
       "  'target': 'patient'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': 'used as', 'target': 'Insulin'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'used as',\n",
       "  'target': 'Sulfonylurea'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'must be taken with',\n",
       "  'target': 'meals'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'given', 'target': 'Adults'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'increased', 'target': 'dosage'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'individualized',\n",
       "  'target': 'basis of both effectiveness and tolerability'},\n",
       " {'source': 'Patients',\n",
       "  'relationship': 'can be titrated from',\n",
       "  'target': 'Dosage'},\n",
       " {'source': 'FDA', 'relationship': 'approve', 'target': 'label'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'may be given to',\n",
       "  'target': 'patients'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be used at',\n",
       "  'target': 'dosage'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'is the usual starting dose of',\n",
       "  'target': 'metformin hydrochloride'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'must be individualized on the basis of',\n",
       "  'target': 'effectiveness and tolerability'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'should be considered for',\n",
       "  'target': 'glycemic control'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'are required, GLUCOPHAGE should be used at',\n",
       "  'target': 'total daily doses'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'should be considered',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used at',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'switched to',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'given with', 'target': 'meals'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'must be individualized',\n",
       "  'target': 'dosage'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'contraindicated',\n",
       "  'target': 'patients with an estimated glomerular filtration rate below 30 mL/minute/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'patients with an eGFR between 30 – 45 mL/minute/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'assess the benefit risk of continuing therapy',\n",
       "  'target': 'patients taking GLUCOPHAGE or GLUCOPHAGE XR whose eGFR later falls below 45 mL/min/1.73 m2'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Discontinuation for Iodinated Contrast Imaging Procedures'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Renal Impairment'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Discontinuation for Iodinated Contrast Imaging Procedures'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'related to',\n",
       "  'target': 'Renal Impairment'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'sulfonylurea'},\n",
       " {'source': 'metformin', 'relationship': 'plus', 'target': 'glyburide'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'concomitant therapy',\n",
       "  'target': 'sulfonylurea'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'concomitant therapy',\n",
       "  'target': 'Insulin'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'concomitant therapy',\n",
       "  'target': 'sulfonylurea'},\n",
       " {'source': 'Insulin', 'relationship': 'Therapy', 'target': 'Patients'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'Therapy', 'target': 'Patients'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': 'Therapy', 'target': 'Patients'},\n",
       " {'source': 'Insulin Dose', 'relationship': 'Decreased By', 'target': '%'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'pregnancy'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'patients below the age of 10 years'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'not recommended',\n",
       "  'target': 'pediatric patients (below the age of 17 years)'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'conservative initial and maintenance dosing',\n",
       "  'target': 'patients with advanced age'},\n",
       " {'source': 'Any dosage adjustment',\n",
       "  'relationship': 'based on',\n",
       "  'target': 'renal function'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': '500 mg'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': '850 mg'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': '1000 mg'},\n",
       " {'source': 'Bristol-Myers Squibb Company',\n",
       "  'relationship': '',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'Merck Santé S.A.S.',\n",
       "  'relationship': 'associate',\n",
       "  'target': 'Merck KGaA'},\n",
       " {'source': 'Bristol-Myers Squibb Company',\n",
       "  'relationship': 'none',\n",
       "  'target': None},\n",
       " {'source': 'Bristol-Myers Squibb Company',\n",
       "  'relationship': 'Licensed to',\n",
       "  'target': 'FDA'},\n",
       " {'source': 'Bristol-Myers Squibb Company',\n",
       "  'relationship': 'Distributed by',\n",
       "  'target': 'Bristol-Myers Squibb Company'},\n",
       " {'source': 'https://www.fda.gov/drugsatfda',\n",
       "  'relationship': 'Visit for current labeling information',\n",
       "  'target': None},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used to treat',\n",
       "  'target': 'type 2 diabetes'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'used to treat',\n",
       "  'target': 'non-insulin-dependent diabetes mellitus'},\n",
       " {'source': 'diabetes', 'relationship': 'causes', 'target': 'kidney damage'},\n",
       " {'source': 'diabetes', 'relationship': 'causes', 'target': 'amputations'},\n",
       " {'source': 'diabetes', 'relationship': 'causes', 'target': 'blindness'},\n",
       " {'source': 'diabetes',\n",
       "  'relationship': 'linked to',\n",
       "  'target': 'heart disease'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'has same active ingredient as',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'helps control',\n",
       "  'target': 'blood sugar'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'works longer in',\n",
       "  'target': 'body'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'helps body respond better to',\n",
       "  'target': 'insulin'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'decreases amount of sugar produced by',\n",
       "  'target': 'liver'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'decreases amount of sugar absorbed by',\n",
       "  'target': 'intestines'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'increases risk of',\n",
       "  'target': 'hypoglycemia'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'may cause',\n",
       "  'target': 'weight gain'},\n",
       " {'source': 'doctor', 'relationship': 'consult', 'target': 'patient'},\n",
       " {'source': 'patient', 'relationship': 'need_to_discuss', 'target': 'doctor'},\n",
       " {'source': 'doctor', 'relationship': 'inform', 'target': 'patient'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'lower', 'target': 'glucose_levels'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'study', 'target': 'children'},\n",
       " {'source': 'Your doctor', 'relationship': 'will tell', 'target': 'you'},\n",
       " {'source': 'You',\n",
       "  'relationship': 'should take',\n",
       "  'target': 'GLUCOPHAGE or GLUCOPHAGE XR'},\n",
       " {'source': 'You',\n",
       "  'relationship': 'will start out with a low dose of the medicine',\n",
       "  'target': 'the medicine'},\n",
       " {'source': 'Your doctor',\n",
       "  'relationship': 'may slowly increase your dose',\n",
       "  'target': 'your blood sugar'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'should be taken with meals',\n",
       "  'target': 'meals'},\n",
       " {'source': 'Your doctor',\n",
       "  'relationship': 'may have you take other medicines',\n",
       "  'target': 'other medicines'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'may help you better control your blood sugar',\n",
       "  'target': 'blood sugar'},\n",
       " {'source': 'GLUCOPHAGE or GLUCOPHAGE XR',\n",
       "  'relationship': 'may help you reduce the insulin dose',\n",
       "  'target': 'insulin'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'mentioned', 'target': 'diabetes'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'causes_harm', 'target': 'liver'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'causes_harm', 'target': 'kidneys'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'mentioned',\n",
       "  'target': 'diabetes'},\n",
       " {'source': 'surgery',\n",
       "  'relationship': 'requires_stop',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'x-ray procedure with injection of dye (contrast agent)',\n",
       "  'relationship': 'requires_stop',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'can affect',\n",
       "  'target': 'other drugs'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'can be affected by',\n",
       "  'target': 'other drugs'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'must be swallowed whole',\n",
       "  'target': None},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'should not be crushed or chewed',\n",
       "  'target': None},\n",
       " {'source': 'alcohol',\n",
       "  'relationship': 'can increase the chance of getting',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'can cause',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'can cause',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'Metformin', 'relationship': 'can lead to', 'target': 'death'},\n",
       " {'source': 'Metformin',\n",
       "  'relationship': 'causes',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'metformin',\n",
       "  'relationship': 'leads to',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'can cause',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE XR',\n",
       "  'relationship': 'can cause',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'severe kidney problems',\n",
       "  'relationship': 'increases risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'certain x-ray tests that use injectable dye',\n",
       "  'relationship': 'affects',\n",
       "  'target': 'kidneys'},\n",
       " {'source': 'liver problems',\n",
       "  'relationship': 'increases risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'alcohol consumption',\n",
       "  'relationship': 'increases risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'dehydration',\n",
       "  'relationship': 'increases risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'surgery',\n",
       "  'relationship': 'can increase risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'heart attack',\n",
       "  'relationship': 'can increase risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'severe infection',\n",
       "  'relationship': 'can increase risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'stroke',\n",
       "  'relationship': 'can increase risk of',\n",
       "  'target': 'lactic acidosis'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Diarrhea'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Nausea'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': '', 'target': 'Upset Stomach'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Diarrhea'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Nausea'},\n",
       " {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': 'Upset Stomach'},\n",
       " {'source': 'Unpleasant Metallic Taste',\n",
       "  'relationship': '',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'Hypoglycemia (Low Blood Sugar)',\n",
       "  'relationship': '',\n",
       "  'target': 'GLUCOPHAGE'},\n",
       " {'source': 'Hypoglycemia (Low Blood Sugar)',\n",
       "  'relationship': '',\n",
       "  'target': 'GLUCOPHAGE XR'},\n",
       " {'source': 'GLUCOPHAGE', 'relationship': 'related_to', 'target': 'GLU'},\n",
       " {'source': 'FDA', 'relationship': 'approved_by', 'target': None},\n",
       " {'source': 'https://www.fda.gov/drugsatfda',\n",
       "  'relationship': 'referenced_url',\n",
       "  'target': None},\n",
       " {'source': 'Merck Santé',\n",
       "  'relationship': 'associate of',\n",
       "  'target': 'Merck KGaA'},\n",
       " {'source': 'GLUCOPHAGE',\n",
       "  'relationship': 'registered trademark of',\n",
       "  'target': 'Merck Santé'},\n",
       " {'source': 'Bristol-Myers Squibb Company',\n",
       "  'relationship': 'licensed to',\n",
       "  'target': 'Merck Santé'}]"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "build_relationships_for_chunks(chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "ffc577ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import json\n",
    "from neo4j import GraphDatabase\n",
    "\n",
    "NEO4J_URI = \"neo4j+s://033a4c34.databases.neo4j.io\"\n",
    "NEO4J_USER = \"neo4j\"\n",
    "NEO4J_PASSWORD = \"yQ02-iiANgP8fMDa_Ndj6mq4DioXPbbqGdP2_JBqrLg\"\n",
    "driver = GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USER, NEO4J_PASSWORD))\n",
    "\n",
    "def sanitize_relationship(rel):\n",
    "    # Uppercase and replace all non-alphanumeric characters with underscores\n",
    "    clean = re.sub(r'[^A-Z0-9_]', '_', str(rel).upper())\n",
    "    return clean if clean else \"RELATED_TO\"  # default if empty\n",
    "\n",
    "def create_relationships_from_json(file_path):\n",
    "    with open(file_path, \"r\", encoding=\"utf-8\") as f:\n",
    "        relationships = json.load(f)\n",
    "\n",
    "    with driver.session() as session:\n",
    "        for rel in relationships:\n",
    "            source = rel.get(\"source\")\n",
    "            relationship = sanitize_relationship(rel.get(\"relationship\", \"RELATED_TO\"))\n",
    "            target = rel.get(\"target\")\n",
    "\n",
    "            if not source or not target:\n",
    "                print(f\"⚠️ Skipping invalid relationship: {rel}\")\n",
    "                continue\n",
    "\n",
    "            query = f\"\"\"\n",
    "            MATCH (a {{text: $source}}), (b {{text: $target}})\n",
    "            MERGE (a)-[r:{relationship}]->(b)\n",
    "            \"\"\"\n",
    "            session.run(query, source=source, target=target)\n",
    "\n",
    "    print(f\"✅ Created {len(relationships)} relationships from {file_path}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "a19eacd2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "⚠️ Skipping invalid relationship: {'source': 'Metformin', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'FDA', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Twice Daily \\nGLUCOPHAGE XR \\n1000', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Plasma Glucose', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'HDL-Cholesterol', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE XR', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE', 'relationship': '', 'target': ''}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE XR', 'relationship': 'antidiabetic drug', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Elderly', 'relationship': 'have decreased hepatic, renal, or cardiac function', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Elderly', 'relationship': 'have concomitant disease or other drug therapy', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Elderly', 'relationship': 'are at higher risk of lactic acidosis', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Elderly patients', 'relationship': 'should have their renal function assessed more frequently', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'Bristol-Myers Squibb Company', 'relationship': 'none', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'https://www.fda.gov/drugsatfda', 'relationship': 'Visit for current labeling information', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE XR', 'relationship': 'must be swallowed whole', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'GLUCOPHAGE XR', 'relationship': 'should not be crushed or chewed', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'FDA', 'relationship': 'approved_by', 'target': None}\n",
      "⚠️ Skipping invalid relationship: {'source': 'https://www.fda.gov/drugsatfda', 'relationship': 'referenced_url', 'target': None}\n",
      "✅ Created 358 relationships from relationships.json\n"
     ]
    }
   ],
   "source": [
    "create_relationships_from_json(\"relationships.json\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9d403c5",
   "metadata": {},
   "source": [
    "### Querying the KG\n",
    "\n",
    "qs: ingestion of what medicine causes diarrhea"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "7e5f6bd3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Diarrhea',\n",
       " 'Drug Interactions',\n",
       " 'CLINICAL PHARMACOLOGY',\n",
       " 'Nifedipine',\n",
       " 'https://www.fda.gov/drugsatfda']"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def query_ent_ext(query):\n",
    "    embedding = model.encode([query], convert_to_numpy=True, normalize_embeddings=True)\n",
    "\n",
    "    retrieved_ent=[]\n",
    "    # --- Search ---\n",
    "    similarities, indices = index.search(embedding, k=5)\n",
    "    results = [(unique_texts[idx], float(sim)) for idx, sim in zip(indices[0], similarities[0])]\n",
    "\n",
    "    # --- Sort descending (already sorted by FAISS) ---\n",
    "    for text, sim in results:\n",
    "        retrieved_ent.append(text)\n",
    "    return retrieved_ent\n",
    "\n",
    "answer = query_ent_ext(query = \"Ingestion of what medicine cause diarrhea\")\n",
    "answer\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "ea46eeef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'relationship': {'properties': {}, 'type': 'TREATS'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Hemoglobin A1c', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Hemoglobin A1c', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Body Weight', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Plasma Glucose', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'GLU', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Diarrhea', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Renal Impairment', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Pediatric', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Placebo', 'label': ['PRODUCT']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Bristol-Myers Squibb Company', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'RELATEDTO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Placebo', 'label': ['PRODUCT']}}, {'relationship': {'properties': {}, 'type': 'RELATEDTO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Metformin', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'ANTIHYPERGLYCEMIC_EFFECT'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Plasma Glucose', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'COMPARABLE_IN'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Hispanics', 'label': ['NORP']}}, {'relationship': {'properties': {}, 'type': 'VS'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Placebo', 'label': ['PRODUCT']}}, {'relationship': {'properties': {}, 'type': 'TENDED_TO_REMAIN_STABLE_OR_EVEN_DECREASE_SOMEWHAT'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Body Weight', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'COMPARED_TO'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Placebo', 'label': ['PRODUCT']}}, {'relationship': {'properties': {}, 'type': 'MONITORED_BY'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Hemoglobin A1c', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'MONITORED_BY'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'serum creatinine', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'RECEIVE'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Metformin', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'USED_IN'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'ages 10 to 16 years', 'label': ['DATE']}}, {'relationship': {'properties': {}, 'type': 'MORE_COMMON_IN'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Placebo', 'label': ['PRODUCT']}}, {'relationship': {'properties': {}, 'type': 'REPORTED_IN'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Diarrhea', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'REGISTERED_TRADEMARK_OF'}, 'node': {'text': 'GLUCOPHAGE', 'label': ['ORG']}, 'connectedNode': {'text': 'Merck Santé', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'Body Weight', 'label': ['PERSON']}, 'connectedNode': {'text': 'GLUCOPHAGE', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'CHANGE_AT_FINAL_VISIT'}, 'node': {'text': 'Body Weight', 'label': ['PERSON']}, 'connectedNode': {'text': '0.9', 'label': ['CARDINAL']}}, {'relationship': {'properties': {}, 'type': 'TENDED_TO_REMAIN_STABLE_OR_EVEN_DECREASE_SOMEWHAT'}, 'node': {'text': 'Body Weight', 'label': ['PERSON']}, 'connectedNode': {'text': 'GLUCOPHAGE', 'label': ['ORG']}}, {'relationship': None, 'node': {'text': 'Twice Daily \\nGLUCOPHAGE XR \\n1000', 'label': ['ORG']}, 'connectedNode': None}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'GLU', 'label': ['ORG']}, 'connectedNode': {'text': 'GLUCOPHAGE', 'label': ['ORG']}}, {'relationship': None, 'node': {'text': 'Serum Lipid \\nVariables', 'label': ['PERSON']}, 'connectedNode': None}]\n"
     ]
    }
   ],
   "source": [
    "def get_entities_with_relationships(driver, entity_texts):\n",
    "    query = \"\"\"\n",
    "    WITH $entityList AS entityList\n",
    "    MATCH (n)\n",
    "    WHERE n.text IN entityList\n",
    "    OPTIONAL MATCH (n)-[r]-(m)\n",
    "    RETURN {\n",
    "        node: {\n",
    "            label: labels(n),\n",
    "            text: n.text\n",
    "        },\n",
    "        relationship: CASE WHEN r IS NOT NULL THEN {\n",
    "            type: type(r),\n",
    "            properties: properties(r)\n",
    "        } ELSE null END,\n",
    "        connectedNode: CASE WHEN m IS NOT NULL THEN {\n",
    "            label: labels(m),\n",
    "            text: m.text\n",
    "        } ELSE null END\n",
    "    } AS result\n",
    "    \"\"\"\n",
    "\n",
    "    with driver.session() as session:\n",
    "        results = session.run(query, entityList=entity_texts)\n",
    "        structured_output = [record[\"result\"] for record in results]\n",
    "    \n",
    "    return structured_output\n",
    "\n",
    "answer = get_entities_with_relationships(driver,query_ent_ext(\"is glucophage related to body weight\"))\n",
    "\n",
    "print(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "5c0add4d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def answer_question_with_graph(driver, question):\n",
    "    # Step 1: Fetch graph data\n",
    "    entity_list=query_ent_ext(question)\n",
    "    graph_data = get_entities_with_relationships(driver, entity_list)\n",
    "\n",
    "    # Step 2: Build a prompt for the LLM\n",
    "    prompt = f\"\"\"\n",
    "You are a reasoning assistant working with a knowledge graph.\n",
    "\n",
    "The graph is given below as JSON. \n",
    "It contains:\n",
    "- \"node\" = the starting node requested\n",
    "- \"relationship\" = the exact relationship (type + properties) between the node and another node\n",
    "- \"connectedNode\" = the node at the other end of the relationship\n",
    "\n",
    "STRICT INSTRUCTIONS:\n",
    "1. Only use relationships that are explicitly shown in the JSON. \n",
    "2. Do NOT make any guesses, assumptions, or use outside knowledge.\n",
    "3. If the answer cannot be found in the relationships, say: \"No direct answer can be found from the provided graph.\"\n",
    "4. Always show the exact chain of relationships from the graph that led to your answer.\n",
    "5. If multiple paths exist, show each path separately.\n",
    "6. If no relationship connects the queried entities, say so clearly.\n",
    "\n",
    "Graph Data:\n",
    "{json.dumps(graph_data, indent=2)}\n",
    "\n",
    "Question: {question}\n",
    "\n",
    "Your response should be in the following format:\n",
    "\n",
    "Answer: <Direct answer based only on relationships in the graph>\n",
    "Relationships used:\n",
    "1. <Node A> -[RELATIONSHIP_TYPE]-> <Node B>\n",
    "2. ...\n",
    "\n",
    "In the end gather whatever you founf out and give a paragraph answer.\n",
    "\"\"\"\n",
    "\n",
    "    print(graph_data)\n",
    "\n",
    "    # Step 3: Send to Ollama\n",
    "    return ask_ollama(prompt)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "8a3f127a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'relationship': None, 'node': {'text': '358 L. Metformin', 'label': ['PERSON']}, 'connectedNode': None}, {'relationship': None, 'node': {'text': 'CLINICAL PHARMACOLOGY', 'label': ['PERSON']}, 'connectedNode': None}, {'relationship': None, 'node': {'text': 'mL. Metformin', 'label': ['PERSON']}, 'connectedNode': None}, {'relationship': None, 'node': {'text': 'Gender \\nMetformin', 'label': ['ORG']}, 'connectedNode': None}, {'relationship': {'properties': {}, 'type': 'RELATED_TO'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'Renal Impairment', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RELATEDTO'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'GLUCOPHAGE', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'IS_INCREASED'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'Cmax', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'ASSOCIATED_WITH'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'Renal', 'label': ['ORG']}}, {'relationship': {'properties': {}, 'type': 'ENHANCE'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'Nifedipine', 'label': ['PERSON']}}, {'relationship': {'properties': {}, 'type': 'RECEIVE'}, 'node': {'text': 'Metformin', 'label': ['PERSON']}, 'connectedNode': {'text': 'GLUCOPHAGE', 'label': ['ORG']}}]\n",
      "Answer: Metformin is related to Renal Impairment, GLUCOPHAGE, Cmax, Renal, and Nifedipine.\n",
      "\n",
      "Relationships used:\n",
      "1. \"Metformin\" -[RELATED_TO]-> \"Renal Impairment\"\n",
      "2. \"Metformin\" -[RELATEDTO]-> \"GLUCOPHAGE\"\n",
      "3. \"Metformin\" -[IS_INCREASED]-> \"Cmax\"\n",
      "4. \"Metformin\" -[ASSOCIATED_WITH]-> \"Renal\"\n",
      "5. \"Metformin\" -[ENHANCE]-> \"Nifedipine\"\n",
      "6. \"Metformin\" -[RECEIVE]-> \"GLUCOPHAGE\"\n",
      "\n",
      "From the provided graph, we can conclude that Metformin is mentioned as being related to several entities. It is related to Renal Impairment through a RELATED_TO relationship, and it is also associated with GLUCOPHAGE through a RECEVE relationship. Additionally, its concentration in plasma (Cmax) is increased, and it is associated with the Renal entity. Furthermore, Metformin enhances Nifedipine's effect.\n"
     ]
    }
   ],
   "source": [
    "# Example usage\n",
    "# question = \"ingestion of what medicine causes diarrhea\"\n",
    "question = \"What all is mentioned about Metformin?\"\n",
    "response = answer_question_with_graph(driver, question)\n",
    "\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aaac9764",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
